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Abstract
The impact of endocrine disruptive chemicals to human and wild life health has raised serious
public health concerns through the past decades. To address this concern, much research was
involved to develop tools for screening and assessing the hormonal potential of these
compounds. Yeast bioluminescent bioreporter assay was one of the tools developed as the result
of these past research endeavors. In this dissertation, a yeast bioluminescent bioreporter assay
system was evaluated for the screening of endocrine disruptors from both experimental and
computational perspectives. The yeast bioluminescent bioreporters were first standardized and
applied in the comparative study of traditional activated sludge and membrane bioreactor
wastewater treatment facilities for their performance in endocrine disruptor removal. Then the
interaction between endocrine disruptors and their target, human estrogen receptor (hER), was
studied by both computational modelling and experimental approaches. Specifically, the effects
of naturally occurring mutations on hER were investigated for their interaction with 29 estrogenic
endocrine disruptors through molecular dynamics simulation and virtual docking. To verify the
predicted results from computational modelling, new yeast bioluminescent reporters harboring
the mutated hER were constructed to evaluate the hER-mediated transactivation triggered by 12
selected endocrine disruptors. hER mutations caused various degree and pattern of changes in
the response to the 12 tested endocrine disruptors in the yeast bioassay. The potential
mechanism for the altered ER mutant response and their possible health related impacts were
discussed.
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Chapter 1. Introduction and Literature Review
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Introduction
Human beings are exposed to a broad spectrum of chemicals that have hormonal potencies.
Since these hormonally active compounds can directly impact and interfere the normal function
of the endocrine system, they are commonly referred as endocrine disruptive chemicals (EDCs).
In recent decades, substantial evidence has been developed that associates the exposure of EDCs
to various human diseases ranging from breast cancer to osteoporosis to developmental
disorders(Diamanti-Kandarakis, Bourguignon et al. 2009). Therefore EDCs have raised significant
public health concern and become a challenging problem to both the government regulators and
scientific community. Due to the prevalence of EDCs in the environment, there is an urgent need
to understand the fate, transport and transformation of EDCs in the environment, and how they
can affect human and animal health. With these central questions, this dissertation provides a
critical development of the application of yeast EDC bioluminescent reporters in the study of
environmental EDC biotransformation in wastewater treatment, and a computational and
experimental perspective on human estrogen receptor mutants and their interaction with EDCs.
The central hypotheses tested in this dissertation are: 1). the hormonal potential of EDCs are
modulated when undergoing the biotransformation process in wastewater treatment and 2).
natural genetic variation in human estrogen receptor can lead to altered susceptibility and
response to different EDCs.
Chapter 2 focuses on the first hypothesis, applying the yeast bioluminescent assay as a highthroughput screening tools to monitor the estrogenic, androgenic potencies and toxicity in the
wastewater treatment systems. The study firstly evaluated the sensitivity and reproducibility of
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the yeast assay through a 7 day semi-continuous batch reactor experiments using the activated
sludge and raw wastewater spiked with hormones. Then this standardized assay was applied in
a 12 month comparative study on the wastewater effluent from the parallel-operated membrane
bioreactor (MBR) and traditional activated sludge (TAS) located at Powell, TN, USA.
Chapter 3 and 4 focus on the second central hypothesis, and specifically examine five selected
human estrogen receptor mutants and their interaction with EDCs from both computational and
experimental perspective. As human estrogen receptor alpha (hERα) features a flexible ligand
binding pocket that may bind many EDCs and modulate the activation of the receptor, research
efforts were concentrated on evaluating the response of the most common receptor form, the
“wild type” human estrogen receptor, that is defined by current understanding of the hERα
protein. However in human genome, small genetic variations, often referred as single nucleotide
polymorphism (SNPs) are found to be ubiquitously present. Previous studies have revealed
numerous hERα mutations on the gene ESR1 in both healthy and cancer patients with primary
and metastatic tumors(Roodi, Bailey et al. 1995, Segal and Dowsett 2014, Thomas and Gustafsson
2015). As these mutations found in ER originated from very limited population, and the incidence
of mutations are far from uncommon, the past EDCs evaluation studies focusing solely on
“wildtype” ER can be incomplete and biased. Consequently this raises a serious issue as to
whether a susceptible subpopulation of hER mutants exist that demonstrates altered
susceptibility or responses to estrogenic and xenoestrogenic chemicals in the environment.
Therefore the studies in Chapter 3 and 4 specifically investigate five mutations of hERα inside or
close to the ligand binding pocket for their effect to the interaction between a broad spectrum
of estrogenic EDCs and the protein receptors. The key questions that were asked are: 1). Does a
3

mutation occurred inside or outside the ligand binding pocket of hER can cause differential
response to estrogenic EDCs? 2). If a mutation on hER causes change of response to natural
estrogen E2, will the direction and degree of deviation also apply to other estrogenic EDCs? To
address these two questions, both computational modelling and experimental yeast
bioluminescent estrogen assay were used to evaluate the binding and transactivation activity of
wildtype and mutant hERα in the presence of EDCs from a wide range of origins (Fig 1.1). It is
hypothesized that binding affinity changes predicted by computational molecular dynamics (MD)
and ensemble docking simulations can provide guideline for experimental transcriptional activity
evaluation using the yeast bioluminescent estrogen reporter.
In Chapter 3, two forms of hERα ligand binding domain, the agonist form and antagonist form,
and five in silico mutated models were subjected in molecular dynamics (MD) simulation. MD
trajectories were clustered to select snapshots from each of the cluster, which were then
computationally docked with a list of 29 estrogenic ligands to evaluate the binding affinity
changes as the result of the mutations.
In Chapter 4, several yeast bioluminescent estrogen reporters using different source of wildtype
hER gene and bioluminescent reporter plasmids were newly constructed. The performance of
these bioreporters was compared and a stable construct was selected and further optimized for
its EDCs testing protocol. Based on this bioreporter construct, five bioreporters containing
separately the five hERα mutations were constructed. A total of 12 EDCs including the natural
estrogen 17β-estradiol (E2), synthetic hormones, plasticizer, phytoestrogen and industrial
compound were evaluated with the wildtype and mutant hER yeast bioreporters.
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Fig 1.1. Scheme of the combined working flow for estrogen receptor mutant and EDCs interaction
study using computational modelling and experimental approaches.
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Literature Review
1.1 The Problem: EDCs in the environment
Magnitude of the problem
Endocrine disruptive chemicals (EDCs) refer to natural and synthetic compounds that can cause
a variety of adverse health effects in human and animals by interfering with the normal function
of endocrine system. EDCs are highly heterologous, consisting of a broad spectrum of compounds
with a wide range of origins and diverse structures.
Commonly known EDCs included natural hormones such as phytoestrogen genistein, coumestrol,
resveratrol, synthetic pharmaceutical such as 17α-ethinyl estradiol (EE2), diethylstilbestrol (DES),
tamoxifen,

plasticizers

such

as

bisphenol

A

(BPA),

pesticides

such

as

dichlorodiphenyltrichloroethane (DDT), and industrial materials such as nonylphenol
etc.(Diamanti-Kandarakis, Bourguignon et al. 2009). Due to the large quantity of synthetic
chemicals being produced by today’s industry, and the fact that a compound’s endocrine
disruptive potential cannot be readily determined by its structural property, the demand for
potential EDCs identification and monitoring is enormous. To address the screening request
enforced by The Federal Food, Drug, and Cosmetic Act (FFDCA 1996), and the Safe Drinking Water
Act Amendments (SDWA 1996), United States Environmental Protection Agency (EPA) initiated
the Endocrine Disruptor Screening Program in 1998 to investigate manufactured chemicals for
endocrine disruptive potential. EPA estimated that over 87,000 new and existing chemicals
require screening for potential endocrine disruptive activities(ICCVAM 2002), a scale that poses
significant challenge to both the scientific community and the government regulators.
6

As EDCs come from very diverse sources, their presence in the environment are nearly ubiquitous.
Since the scientific community reached a general consensus about the potential health impact of
EDCs in early 1990s, many following investigations have been conducted to trace the presence
of EDCs in the environment and the potential exposure pathway to human and animals(Colborn
and Clement 1992). For human beings, exposure to EDCs are primarily through oral consumption,
skin contact or inhalation. Through oral consumption, humans are exposed to EDCs such as
residual pesticides on food (e.g. vinclozolin), leached chemicals of packaging (e.g. bisphenol A),
phytoestrogens in soy-based food and dietary supplements (e.g. genistein, resveratrol), synthetic
hormones in contraceptives and hormone therapy drugs (e.g. EE2, tamoxifen) etc. Skin contact
is another route of exposure to the EDCs present in cosmetics, personal care products etc (e.g.
phthalates, triclosan). Certain EDCs such as flame retardants brominated diphenylethers (BDEs)
can also enter human body through inhalation (Diamanti-Kandarakis, Bourguignon et al. 2009).
Compared to human beings, wild animals have high chance of exposure to EDCs released into the
environment due to human activity. Numerous previous studies have reported that many natural
and synthetic EDCs are persistent at various level in soil, sediment, surface and ground water,
and even drinking water (Kolpin, Furlong et al. 2002, Lintelmann, Katayama et al. 2003, Ying and
Kookana 2005, Benotti, Trenholm et al. 2008, Focazio, Kolpin et al. 2008). The contamination of
EDCs in the aquatic environment has the most impact on aquatic organisms due to persistent
exposure to EDCs in the habitat, while other animals exposed by the contaminated water or prey
are also affected. Investigating and controlling the contamination of environmental EDCs is a
rather demanding task since EDCs in the environment consists of a mixture of natural and
synthetic hormones, and industrial compounds, and their occurrence, fate, transition also varies
7

depends on the specific geological location. The release of environmental EDCs can be mainly
attributed to municipal and industrial wastewater effluent, agricultural runoff, occasional
chemical spills and commercial product use and disposal. Among these sources, wastewater
effluent contributes to the majority of environmental EDCs, as incomplete removal of organic
contents in industrial and municipal sewage lead to continuous discharge of hormonally active
compounds into the downstream watershed(Liu, Kanjo et al. 2009).
Health Impact of EDCs to human and wildlife
The human endocrine system includes a series of glands spread across the entire body (Fig. 1.2).
These glands are responsible for producing a variety of hormones, which are small molecules
circulated throughout the body to regulate critical physiological functions. The way hormones
exert regulatory function is by binding to its specific protein receptors in the targeted tissues,
triggering a variety of responses. Through the endocrine system, many critical functions ranging
from homeostasis, metabolism, sexual development, reproduction, gender behavior etc. are
maintained (Diamanti-Kandarakis, Bourguignon et al. 2009). EDCs could affect the endocrine
system in several ways that either mimic natural hormones to bind to the receptors, block the
receptors, or interfere the production/depletion of natural hormones/receptors. The endocrine
system consists of complex components and mechanistically each type of hormones produced in
the endocrine system plays specific and unique roles in maintaining the normal function of
human body. Thus potentially any physiological function that relies on the regulation of
endocrine system can be affected by EDCs.
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The discovery of EDCs’ effect on human health can be traced back to the usage of the synthetic
hormone diethylstilbestrol (DES) since 1940, which was initially prescribed for preventing
miscarriage in women. DES was banned by Food and Drug Administration (FDA) in 1971 due to
the increased developmental birth defects and incidences of vaginal cancer in many women that
received the treatment(Marty, Carney et al. 2011). As man-made chemicals being widely used in
the industry and agriculture, a growing number of studies reported abnormal development and
behaviors in wild animals (bird, fish etc.) including decreased fertility, decreased hatching success,
feminization of male and defeminization of female etc., which was later attributed to the
exposure of environmental EDCs in their habitats(Colborn and Clement 1992, Colborn, vom Saal
et al. 1993). Since then, EDCs have been associated with numerous hormone mediated problems
such as reduced reproducibility, birth defects, abnormal development, osteoporosis, obesity,
breast cancer, etc.(Soto and Sonnenschein 2010, De Coster and van Larebeke 2012, Frye, Bo et
al. 2012, Spencer, Dunlap et al. 2012). EDCs’ adverse effect is of particular concern for fetus and
newborn, as the hormonal balance in this critical stage of life is very delicate and interference
from EDCs could possibly cause permanent effect(Haddow, Palomaki et al. 1999).
Microbial reduction of EDC potential in wastewater treatment
Wastewater effluent is the largest source of EDCs discharged into the environment. Since the
EDCs contained in the wastewater effluent can lead to further contamination into the surface
water, ground water, sediments and soil etc., effective removal of EDCs from wastewater at the
treatment facilities is pivotal. Generally EDC removal at wastewater treatment plants (WWTP)
can be classified into three categories : 1) physical separation such as activated carbon adsorption,
membrane rejection, 2) biotransformation and degradation by concentrated microbial biomass,
9

3) chemical advanced oxidation by O3, H2O2 etc.(Liu, Kanjo et al. 2009). However, due to the high
cost of physical separation and chemical oxidation technology, most WWTPs rely on
concentrated microbial biomass, activated sludge, to metabolize and remove organic pollutants
including EDCs. Historically, the commonly used activated sludge in WWTP was primarily
designed with aim of removing phosphorus and nitrogen contents in the wastewater. Therefore
as EDCs discharge become a serious environmental concern, many studies reexamined the
processing of WWTPs regarding their performance on trace organic chemical and EDCs removal.
The reported data from both field WWTP monitoring and lab-scale simulation experiments
suggest that EDC removal by current WWTP processing is incomplete, and the efficiency of EDC
removal varies greatly depending on the type and level of influent EDCs, technical setting and
operational parameters of the WWTPs(Liu, Kanjo et al. 2009). Some chemicals such as estrone
(E1) and 17β-estradiol (E2) can have over 90% removal, while other chemicals such as 17αethynylestradiol (EE2), nonylphenol etc. are more persistent in the wastewater treatment
system(Clara, Strenn et al. 2005, Drewes, Hemming et al. 2005, Chimchirian, Suri et al. 2007). As
EDCs persist in the effluent of WWTPs, much research has focused on improving the efficiency of
EDC removal in wastewater treatment and improving monitoring protocols. Apart from
optimizing WWTP operational parameters such as mixed liquor suspended solid (MLSS)
concentration, solid retention time (SRT), hydraulic retention time (HRT) etc, new secondary or
tertiary treatment technologies such as membrane bioreactors, ozonation and advanced
oxidation processes, activated carbon adsorption etc. were developed and studied for their EDC
removal efficiency(Chang, Choo et al. 2009, Luo, Guo et al. 2014). Since EDC removal efficiency
can be affected by the treatment technologies as well as the properties and contents of the
10

Fig 1.2. Diagram of major endocrine glands in human body. Adapted from (Diamanti-Kandarakis,
Bourguignon et al. 2009).
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wastewater, effective screening tools are required to monitor and evaluate the performance of
WWTPs. During wastewater treatment, reduction of a parent compound doesn’t necessarily
result in reduced biological activity as the biotransformed products could still have potent or
even augmented hormonal activity. Therefore when assessing the EDC removal efficacy in
wastewater treatment, besides tracking the fate of the targeted compound, it is necessary to
evaluate the changes in biological activities as well.
Screening assays and analytical methods for EDCs
Typically, detection of EDCs can be achieved by traditional mass-based methods (i.e. gas
chromatography or liquid chromatography coupled mass spectrometry etc.), or biologically
based methods. Biological assays were developed in a variety of forms that can be classified into
three general categories, in vivo whole organism assays, in vitro cell-based assays and in vitro
cell-free assays.
To determine the endocrine disrupting potential of a compound, the ideal methodology is
through in vivo toxicological exposure experiments with whole organism models. However, the
large quantity of chemicals that require screening for endocrine disruptive potential make it
impossible to rely on animal models due to time, fiscal constraints and animal welfare concerns.
To tackle this challenge, U.S. EPA proposed a two-tiered screening program, with tier 1 focuses
on high-throughput priorization of chemicals that have potential to interact with the endocrine
system, and tier 2 further determines the specific effects and dose response caused by each
identified chemical(Rotroff, Dix et al. 2013). In response, the scientific community developed a
variety of in vitro and in vivo assays to fulfill the need of tier 1 and tier 2 screenings. These assays
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are not only used for single chemical testing, but are also widely used for evaluating the biological
activity of mixture EDCs and environmental sample monitoring.
Traditional analytical methods usually employ mass spectrometry to provide targeted analysis of
compounds available in the database. Typically, mass-based method requires sample
extraction/concentration through liquid/solid phase extraction. In sample detection, mass
spectrometry is usually coupled with sample separation instrument such as liquid chromatograph
or gas chromatograph(Chang, Choo et al. 2009). As a widely used analytical tool, mass-based
methods have high sensitivity, high specificity and excellent quantitative ability, therefore very
suitable for detecting trace level EDCs in samples. Nevertheless, mass-based detection requires
costly investment on specialized equipment and personnel training, hindering its application for
large scale screening tasks. In addition, mass-based methods rely on pre-knowledge of a
chemical’s structural property and is unable estimate the biological activity of EDCs, making it
less practical especially when the sample contains unknown or a mixture of EDCs. In these cases,
screening with biological assays are necessary to ensure comprehensive evaluation of the
endocrine disruptive activities.
Currently studies on the biological effects of EDCs primarily focus on their interference with the
estrogen, androgen and thyroid hormone mediated functions, though estrogen related studies
account for the majority because the number of known estrogen related health problems seem
to far exceed the others. To study the hormonal activity of a specific compound, both in vitro and
in vivo assays are commonly used, with each offering distinct advantages. In vivo assays employ
model animals such as amphibian, fish or mouse to evaluate EDCs’ biological effect. This type of
assay monitors the organism’s changes in morphology such as size, reproduction function such
13

as fertility rate, or internal biomarkers such as key protein expression level, as the results of EDC
exposure. For example, the expression of vitellogenin, an egg yolk precursor protein, was widely
used as the indicator of estrogenic response in male fish models including zebrafish, sheephead
minnow, madaka etc.(Folmar, Hemmer et al. 2000, Rose, Holbech et al. 2002, Kurauchi,
Nakaguchi et al. 2005). For evaluation of EDCs’ effects on mammals, mouse models provided
several different assays to evaluate interference of estrogen, androgen, steroidgenesis and
thyroid related functions(Gray, Wilson et al. 2004). For example, ovariectomized mouse based
uterotropic assay (measure the weight change of uterus), and pubertal female assay (measure
early opening of vagina), were commonly used to determine the estrogenic activity of EDCs(Kim,
Shin et al. 2002, Ohta, Takagi et al. 2012, Hewitt, Winuthayanon et al. 2015). Hershberger assay
and pubertal male assay (both measure weight change of androgen-related organs) were used
to determine EDCs affecting androgen and thyroid related functions(Gray, Furr et al. 2001, Marty,
Crissman et al. 2001). The main advantage of in vivo assays is that test results represent the actual
reaction of the organism to the exposure of tested EDCs. As the endocrine system involves
complex pathways, it is necessary to incorporate in vivo assays in order to properly evaluate the
systematic reaction of the entire endocrine system. In vivo assays are also particularly suitable
for evaluating the effect of exposure to a mixture of EDCs, as well as long-term environmental
exposure evaluation.
Compared to in vivo assays, in vitro assays can be performed much quicker with lower cost,
therefore are very suitable for large scale screening while still being able to provide biologically
relevant EDCs potency evaluation. Most in vitro assays were designed to examine the ability of
EDCs to interact with the targeted receptor protein (i.e. estrogen receptor). For example, ligand
14

identification with estrogen receptor has been successfully developed in the cell free form such
as enzyme-linked receptor assay (ELRA), as well as a commercially available fluorescent receptorbinding assay etc.(Seifert, Haindl et al. 1999, Wittliff, Andres et al. 2008). Cell based in vitro assays
typically examines the activation of hormonal receptors by EDCs, and generate the response
signal through receptor-dependent expression of reporter genes. Since the 1990s, a variety of
cell based bioreporter assays were developed using both yeast and mammalian cell lines(Leusch,
de Jager et al. 2010). These bioreporters express hormonal receptors such as estrogen/androgen
receptor (endogenous or artificially introduced), and harbor reporter gene expression cassette
that is controlled by the hormone response element, a short sequence of DNA within the
promoter that directly interacts with the hormone receptor complex. While the fundamental
mechanism of these reporters are similar, selected reporter genes varied from β-galactosidase,
green fluorescent protein to different type of luciferases (Routledge and Sumpter 1996, Bovee,
Helsdingen et al. 2004, Sanseverino, Eldridge et al. 2009).
Among the different type of bioreporters, yeast bioluminescence reporters Saccharomyces
cerevisiae BLYES, BLYAS and BLYR were developed with the aim of being a high-throughput,
sensitive, rapid and low-cost EDCs screening tool (Sanseverino, Gupta et al. 2005, Eldridge,
Sanseverino et al. 2007). BLYES, BLYAS and BLYR were designed as fully autonomous
bioluminescent strains to detect estrogenic, androgenic or toxic compounds respectively. BLYES
and BLYAS were developed on the basis of two S. cerevisiae strains expressing chromosomally
maintained human estrogen receptor alpha and human androgen receptor gene
respectively(Purvis, Chotai et al. 1991, Routledge and Sumpter 1996). These strains were further
engineered to carry the bioluminescence gene cassette luxCDABE from Photorhabdus
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luminescens, and the expression of lux genes are either constitutive for cytotoxicity detection
(BLYR), or controlled by estrogen response element (BLYES) (Fig 1.3), and androgen response
element (BLYAS). Upon exposure to estrogenic or androgenic compounds, BLYES and BLYAS can
provide quantitative measurement through dose-dependent bioluminescence production. BLYR
can provide cytotoxicity evaluation through bioluminescence reduction. The yeast
bioluminescent reporters strains have been successfully used in various applications including
the screening of 71 chemicals for hormonal and toxic effects(Sanseverino, Eldridge et al. 2009),
surface and drinking water estrogenicity evaluation in Brazil(Di Dea Bergamasco, Eldridge et al.
2011), estrogenicity/androgenicity evaluation for plastic monomer and biotransformed EDCs(Lee,
Zhao et al. 2012, Osimitz, Eldridge et al. 2012, Krifaton, Kriszt et al. 2013), estrogenicity evaluation
in municipal sewage and sludge(Ruan, Liang et al. 2015, Wang, Eldridge et al. 2015). Compared
to mass-based chemical analysis, yeast bioluminescent assays can provide biologically relevant
estimation on the cumulative effect of hormonally active compounds in environmental samples
without having to identify the individual compound. Additionally, yeast bioluminescent reporters
have comparable detection sensitivity as chemical analysis, respond quickly (≤ 4 hours), and can
test samples in high-throughput at much lower costs, resulting in a suitable screening tool for
wastewater EDCs that can be combined with chemical analysis when more targeted analysis is
required.
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Fig 1.3. Schematic of bioluminescent yeast estrogen reporter. Human estrogen receptor protein
was chromosomally integrated and expressed in the yeast. When estrogen receptor is activated
by estrogenic compound, it binds to the estrogen response element (ERE) sequence on the
plasmid, triggering the expression of the plasmid to produce luciferase and light.
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1.2 Human Estrogen Receptor Protein
Structure of ER
Human estrogen receptors (hER) are members of the nuclear receptor superfamily that mediates
estrogen regulated physiological and reproducible functions as transcriptional factors. So far two
hER genes, ESR1 and ESR2, have been identified in human, with each coded protein referred as
ERα and ERβ in the order of discovery(Thomas and Gustafsson 2011). Similar to other members
of the nuclear receptor family, both ERα and ERβ protein have 6 functional domains (Fig 1.4): the
N-terminal A and B domain, which contain the ligand-independent activation function 1 (AF-1),
DNA binding domain (DBD), which is responsible to bind to DNA sequence referred as estrogen
response element (ERE), a flexible hinge domain, and a C-terminal ligand binding domain (LBD)
that contains ligand-dependent activation function 2 (AF-2). The full length ERα and ERβ are 595
and 530 amino acids respectively. ERα and ERβ share very high homology in the DNA binding
domain (96%), moderate homology in the ligand binding domain (53%), and very low in A/B
domain (30%). ERα and ERβ expression has different tissue distribution, and their individual
function still remains to be cleared, though in breast cancer, ERα is expressed in ~70% of tumors
with significantly higher level than ERβ(Böttner, Thelen et al. 2014, Thomas and Gustafsson 2015).
This present study solely focused on ERα.
Crystal structures are only available for the DBD and LBD of ER (Fig 1.5). The lack of whole ER
protein crystal structure is partly due to intrinsic flexibility of the hinge domain that hinders the
formation of crystal. The AF-1 domains lacks defined structure in solution but forms secondary
structure when interacting with coregulators(Rajbhandari, Finn et al. 2012). The DBD is a
18

Fig 1.4. Schematic representation of the functional structure of estrogen receptor alpha and beta.
The structural domains are labeled A-F and the number of amino acids are labeled in purple. The
location of the functional domains are marked in purple bars. Region A and B contains the ligandindependent activation function 1 (AF1). Region C is the DNA binding domain responsible for
binding to estrogen response element (ERE). Region D is the flexible hinge domain. Region E is
ligand binding domain, contains the ligand-dependent activation function 2 (AF2).
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Fig 1.5. Crystal structure of estrogen receptor DNA binding domain (A) and ligand binding domain
(B).
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conserved domain in nuclear receptor, contains two zinc fingers that recognize the ERE
sequence(Schwabe, Chapman et al. 1993). The C-terminal LBD is consisted of 12 alpha helix (H112) that forms a hydrophobic ligand binding cavity responsible for high affinity binding of
estrogens. Besides ligand binding, the AF-2 region of the LBD is responsible to recruit various coregulatory proteins that are required for ER’s transcriptional activity. The LBD is also involved in
receptor dimerization that is necessary for DBD to bind to the ERE sequence(Brzozowski, Pike et
al. 1997).
Transcriptional activation by ER
As transcriptional factors, ERs’ regulatory function can be either estrogen-dependent or
independent. The estrogen-independent transcriptional activation function is fulfilled by the AF1 domains, and the function can be controlled by phosphorylation through the MAPK
pathway(Rajbhandari, Finn et al. 2012). The estrogen-dependent transcriptional regulation is the
primary machinery for ER to respond to the serum level change of estrogens and mediate the
regulatory functions. Upon binding of estrogens, ER undergoes conformational changes that
further lead to receptor dimerization, binding to ERE sequence, recruitment of coregulator and
other components in the transcriptional complex to regulate gene expression (Fig 1.6).
Agonist and antagonist ligand-receptor interaction
The binding pocket of the DBD has a flexible helix-12 that, depends on the type of ligand, the
helix-12 can undergo an open or closed position (Fig 1.7). When agonist such as natural estrogen
bind to the pocket, helix-12 can successfully close the binding pocket, allowing co-activator to
bind to the protein. However an antagonist such as 4OH-tamoxifen has a long side chain that
21

Fig 1.6. Schematic of estrogen-dependent transcriptional regulation by estrogen receptor. Ligand
binding activates the ER to dimerize, bind to estrogen response element (ERE) sequence within a
promoter, recruit co-activators and other components in the transcriptional complex.
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Fig 1.7. Agonist-bound form and antagonist-bound form of estrogen receptor ligand binding
domain. When bound by agonist, helix-12 (marked in brown) is in the closed position, while
antagonist binding will disturb the positioning of helix-12 to close the binding pocket.
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perturb the positioning of helix-12, rendering an open position that disrupt the co-activator
binding surface(Brzozowski, Pike et al. 1997, Shiau, Barstad et al. 1998). The ligand binding pocket
of ERα consists of mostly hydrophobic amino acids with several charged residues providing
critical electrostatic interaction with ligands (Fig 1.8). When bound by natural estrogen 17βestradiol, the charged side chain of Glu353 and Arg394, along with a water molecule form a
hydrogen network that interacts with the phenolic hydroxyl group of the ligand. On the other
end of the ligand, His524 forms a hydrogen bond with the hydroxyl group of the ligand as well.
Other hydrophobic residues further shape the binding cavity, providing a hydrophobic “clamp”
to properly position the ligand. Due to the flexibility of ER ligand bind pocket, many natural and
artificial compounds other than natural estrogens can also bind to the DBD and exert either
agonist or antagonist effect. This is the main reason why many structurally diverse EDCs can
interact with estrogen receptor.
ER mutations and human disease
As ER plays vital role in human physiology and reproduction, there has been considerable interest
in identifying and associating mutations in ER with human diseases. However, since the finding
of the first missense naturally occurring ERα mutation (Ala86Val) in breast cancer in 1988, natural
mutations in ERα are rarely reported in primary diseases(Garcia, Lehrer et al. 1988). The reported
polymorphisms in the ERα gene that alter the protein sequence are predominantly related to
breast cancer tissues, though other health problem including endometrial cancer, physiological
and developmental disorder were also involved(Herynk and Fuqua 2004, Li, Liu et al. 2005,
Quaynor, Stradtman et al. 2013). Some notable mutations include Ala86Val located at the AF-1
domains, Lys303Arg located at border of the hinge and LBD, Tyr537Ser located at the LBD etc.
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Fig 1.8. Natural estrogen 17β-estradiol in hER alpha binding pocket. (A) 3D demonstration of the ligand in the pocket (PDB entry: 1A52).
Binding pocket surface is represented in the net surface, with green representing a hydrophobic surface, purple and red representing
polar surfaces. (B) 2D schematic of the ligand-protein interaction. Glu353 and Arg394 provide critical electrostatic interaction (forming
a hydrogen bond network with a water molecule) with the phenolic hydroxyl group of the ligand. These two residues are necessary
for the ligand to properly position in the binding pocket. On the other side of the binding pocket, His524 provide critical hydrogen
bond interaction with the ligand as well. The rest of the residues provide hydrophobic environment on the two sides of the ligand,
forming a hydrophobic “clamp” around the ligand.
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The situation of the limited ER mutant reports in the literature was changed since 2013, when
several groups revealed numerous mutations of ERα in metastatic breast cancer tissues, with
some occuring at much higher high frequency than previously known(Merenbakh-Lamin, BenBaruch et al. 2013, Robinson, Wu et al. 2013, Toy, Shen et al. 2013, Jeselsohn, Yelensky et al.
2014). These studies find that breast cancer patients can acquire resistance to anti-estrogen
therapy as the result of a few point mutations occurred at Tyr537 and Asp538 on Helix-12 of the
LBD. The mutations at Tyr537 and Asp538 can induce Helix-12 to stay in the closed position,
making the ER constitutively active and subsequently promote the proliferation of tumor cells,
thus making anti-estrogen drug such as tamoxifen ineffective(Thomas and Gustafsson 2015).
When collecting all the recent clinical screening studies on ESR1 gene, it is clear that the majority
of mutations occur at the ligand binding domain (Fig 1.9). When analyzing these clinical studies
together, the mutation rate in ERα in primary tissues was only about 1% among all the patients,
while mutation frequency in metastatic tissue reached around 19%(Segal and Dowsett 2014).
These recent studies provided substantial evidence that mutations naturally occurring on the LBD
of ERα are directly involved in the development of breast cancer, and their roles in interfering
the interaction between the ER and its ligands, be it the natural estrogen, anti-hormone drugs or
estrogenic EDCs, require further in-depth investigation to allow better control of ER-involved
cancers.
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Fig 1.9. Schematic of human estrogen receptor alpha functional domains and natural mutations
found in breast cancer. Mutations found in primary and metastatic breast cancer tumors
reported in previous studies(Roodi, Bailey et al. 1995, Segal and Dowsett 2014, Thomas and
Gustafsson 2015) are marked in red. The structural domains are labeled A-F and the number of
amino acids are labeled in purple. The location of the functional domains are marked in purple
bars. Region A and B contains the ligand-independent activation function 1 (AF1). Region C is the
DNA binding domain responsible for binding to estrogen response element (ERE). Region D is the
flexible hinge domain. Region E is ligand binding domain, contains the ligand-dependent
activation function 2 (AF2).
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Chapter 2. Assessing Microbial Modulation of EDC Potential in
Wastewater Treatment Using Yeast Bioluminescent Reporters
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Abstract
A standardized protocol is demonstrated for bioluminescent strains Saccharomyces cerevisiae
BLYES, BLYAS and BLYR as high-throughput screening tools to monitor the estrogenic, androgenic
and toxic potencies in wastewater. The sensitivity and reproducibility of the assay in wastewater
monitoring was evaluated for 7 day semi-continuous batch reactor using activated sludge with
hormones spiked raw sewage. Yeast bioluminescent assay successfully captured the rapid
removal of estrogenic and androgenic activities in the bioreactors, and demonstrated rapid
response (≤ 4 hrs) with good reproducibility. This standardized protocol was then applied in a 12
months monitoring of the effluent of a WWTP located at Powell, TN, USA featuring paralleloperated full-scale membrane bioreactor (MBR) and traditional activated sludge (TAS) treatment.
Monitoring results showed that estrogenic activity was persistent in all TAS and most MBR
effluent samples, while residual androgenic activity was non-detectable throughout the
monitored period. The estrogenic equivalents (EEQ) in TAS effluent ranged from 21.61 ng/L to
0.04 pg/L and averaged 3.25 ng/L. The EEQ in MBR effluent ranged from 2.88 ng/L to 0.0134 pg/L
and averaged ~10 fold less (0.32 ng/L) than TAS. Despite the large temporal variation, MBR
effluent EEQ was consistently lower than TAS on any given sampling date. Most MBR effluent
samples also exhibited less cytotoxicity than TAS. Further analysis did not demonstrate significant
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correlation between effluent EEQ level and WWTP operational parameters including MLSS, SRT,
HRT and BOD.

2.1 Introduction
Endocrine disruptors (EDCs) refer to natural and synthetic chemicals that can cause a variety of
adverse health effects in human and animals by interfering with the function of endocrine system.
Commonly

studied

EDCs

included

natural

hormones

such

as

17β-estradiol

and

dihydrotestosterone, synthetic hormones such as 17α-ethinyl estradiol, phytoestrogens such as
genistein, and industrial materials such as bisphenol A or nonylphenol etc(Liu et al. 2009). Since
the potential health risk of EDCs was initially discovered, EDCs are implicated in numerous
hormone related problems such as reduced reproducibility, birth defects, abnormal development,
osteoporosis, breast cancer, etc
(Frye et al. 2012; Kabir et al. 2015). Due to human activities and waste discharge, EDCs are
suggested as a cause of reproductive abnormities in wildlife, and have been detected in surface,
ground and drinking water around the world (Kim et al. 2007; Kolpin et al. 2002; Luo et al. 2014).
One of the major sources of environmental EDCs is industrial and municipal sewage. As the
primary barrier preventing the release of EDCs into the aquatic environment, most wastewater
treatment plants (WWTP) rely on concentrated microbial biomass, activated sludge, to
metabolize and remove organic pollutants including EDCs. However the commonly used
activated sludge in WWTP isn’t specifically designed for trace organic chemical removal and
residual EDCs are continuously discharged from WWTPs at various concentrations (Liu et al.
2009). As the concern over the health and ecological risk of environmental EDCs persists, much
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research has focused on improving the efficiency of EDC removal in wastewater treatment and
improving monitoring protocols. Apart from optimizing WWTP operational parameters such as
mixed liquor suspended solid (MLSS) concentration, solid retention time (SRT), hydraulic
retention time (HRT) etc, new secondary or tertiary treatment technologies such as membrane
bioreactors, ozonation and advanced oxidation processes, activated carbon adsorption etc. were
developed and studied for their EDCs removal efficiency(Chang et al. 2009; Luo et al. 2014). Since
EDCs removal efficiency can be affected by the treatment technologies as well as the properties
and contents of the wastewater, effective screening tools are required to monitor and evaluate
the performance of WWTPs. During wastewater treatment, reduction of a parent compound
doesn’t necessarily result in reduced biological activity as the biotransformed products could still
have potent or even augmented hormonal activity. Therefore when assessing the EDCs removal
efficacy in wastewater treatment, besides tracking the fate of the targeted compound, it is
necessary to evaluate the changes in biological activities as well.
In the need of effective EDCs evaluation in wastewater treatment, yeast bioluminescence
reporters Saccharomyces cerevisiae BLYES, BLYAS and BLYR have shown great potential of being
a high-throughput, sensitive, rapid and low-cost EDCs screening tool (Eldridge et al. 2007;
Sanseverino et al. 2005). BLYES, BLYAS and BLYR were previously developed as fully autonomous
bioluminescent strains to detect estrogenic, androgenic or toxic compounds respectively. BLYES
and BLYAS were developed on the basis of two S. cerevisiae strains expressing chromosomally
maintained human estrogen receptor alpha and human androgen receptor gene
respectively(Purvis et al. 1991; Routledge and Sumpter 1996). These strains were further
engineered to carry the bioluminescence gene cassette luxCDABE from Photorhabdus
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luminescens, and the expression of lux genes are either constitutive for cytotoxicity detection
(BLYR), or controlled by estrogen response element (BLYES) and androgen response element
(BLYAS). Upon exposure to estrogenic or androgenic compounds, BLYES and BLYAS can provide
quantitative measurement through dose-dependent bioluminescence production. BLYR can
provide cytotoxicity evaluation through bioluminescence reduction. The yeast bioluminescent
reporters strains have been successfully used in various applications including the screening of
71 chemicals for hormonal and toxic effects(Sanseverino et al. 2009), surface and drinking water
estrogenicity evaluation in Brazil(Di Dea Bergamasco et al. 2011), estrogenicity/androgenicity
evaluation for plastic monomer and biotransformed EDCs(Krifaton et al. 2013; Lee et al. 2012;
Osimitz et al. 2012), estrogenicity evaluation of bisphenol analogs in municipal sewage
sludge(Ruan et al. 2015). Compared to mass-based chemical analysis, yeast bioluminescent
assays can provide biologically relevant estimation on the cumulative effect of hormonally active
compounds in environmental samples without having to identify the individual compound.
Additionally, yeast bioluminescent reporters have comparable detection sensitivity as chemical
analysis, respond quickly (≤ 4 hours), and can test samples in high-throughput at much lower
costs, resulting in a suitable screening tool for wastewater EDCs that can be combined with
chemical analysis when more targeted analysis is required.
The main objectives of the present study are: (a) to present a standardized protocol using yeast
bioluminescent reporter assay for high-throughput wastewater EDC screening, (b) to
demonstrate the sensitivity, reproducibility of the assay in wastewater monitoring, and (c) to
apply the yeast bioluminescent reporters in a long-term comparative study on parallel-operated
full-scale membrane bioreactor (MBR) and traditional activated sludge (TAS). Lab-based semi37

continuous bioreactors were initially used to test the sensitivity and reproducibility of the
standardized yeast assay in capturing the rapid change of hormonal activities in the bioreactors.
Then the assay was employed in a 12 months monitoring of effluent from parallel-operated fullscale TAS and MBR located at Powell, TN, USA. In prior studies, MBR and TAS were compared
either on lab or pilot scale plants, or were compared on different locations (Clara et al. 2005b;
Kimura et al. 2007; Vega-Morales et al. 2013). This study provides the first long-term
performance assessment and comparison on the EDCs discharge at a full-scale WWTP with
parallel-operated MBR and TAS. The androgenic, estrogenic and toxic activities in monitored MBR
and TAS effluent were reported and their correlation with key operational parameters were
analyzed. The complete wastewater testing protocol including sample preparation, bioassay
setup, and data analysis is described in full detail. The issue of wastewater toxicity in yeast
bioassay, estrogenic equivalent calculation and result interpretation are also discussed.

2.2 Materials and Methods
Chemicals
Natural estrogen 17β-estradiol (E2, CAS# 50-28-2), synthetic estrogen ethinyl estradiol (EE2,
CAS# 57-63-6) and natural androgen 5α-dihydrotestosterone (DHT, CAS# 521-18-6) were
purchased form Sigma-Aldrich. High performance liquid chromatography (HPLC) grade methanol,
acetone and acetonitrile were purchased from Fisher Scientific.
Sampling site
Wastewater influent, effluent and activated sludge samples were taken from Hallsdale-Powell
Utility District (HPUD) Beaver Creek Wastewater Treatment Facility at Powell, Tennessee, USA.
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This plant serves approximately 22,000 customer accounts covering ~260 km2. The maximum
wastewater processing capacity of the entire plant is ~ 45,000 m3 per day. The wastewater
influent of this plant consists mostly sanitary domestic sewage, as well as three major industrial
users including a bread baking operation, a milk processing facility and a meat repackager. The
plant operates with two parallel facilities including a traditional activated sludge (TAS) coupled
with secondary clarifiers, and a membrane bioreactor (MBR) featuring immersed GE ZeeWeed500 (originally ZENON, Oakville, Ontario) Hollow-Fiber membranes. Raw wastewater influent is
pretreated by coarse screening, grit and grease removal, and then separated into either TAS or
MBR feed to be treated. Effluents from TAS and MBR are discharged together into Beaver Creek.
Operational parameters of the wastewater facility were monitored and provided by HPUD for
this study. Parameters monitored separately for TAS and MBR included MLSS, MLVSS, solid
retention time (SRT), hydraulic retention time (HRT), food/microbe ratio (F/M ratio). Other
operational parameters monitored for the influent and effluent of the entire plant and included
the total flow, carbonaceous 5-day biological oxygen demand (cBOD5), suspended and settled
solid, dissolved oxygen and ammonia content.
Semi-continuous fill & draw lab-scale bioreactor experiment
Activated sludge and raw wastewater were sampled from HPUD in pre-baked (500 °C for 4 hours)
bottles and transported in icebox to the lab. Raw wastewater was immediately filter (0.22 µm)
sterilized and kept in dark at 4 °C before feeding the bioreactors. Fill & draw bioreactor
experiments were started on the same day of sampling. Two experiments (Table 2.1) was
performed using the activated sludge from the TAS and MBR respectively. At the time of sampling,
MLSS in TAS was ~2500 mg/L, while the MLSS in MBR was ~8500 mg/L. Since the biosolid
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concentration in the MBR is higher than that in the TAS, the spiked chemical concentrations were
increased 10 fold in the second experiment.
In each experiment, 3 groups of 100 mL bioreactors in triplicate were set up in the lab (Fig. 2.1),
including (1) activated sludge (AS), (2) activated sludge with spiked hormones (AS+), (3) filtered
raw wastewater (- control). Bioreactors were maintained at 28 °C, 200 rpm and the fill & draw
operations continued for 7 days. In each day 30 mL mixed liquid were taken out of each
bioreactor and re-filled with filtered raw wastewater (group 2 were also spiked with hormones).
Collected samples were centrifuged for 10 minutes at 5000 rpm to separate the liquid and solid
phase. The separated solid phases in the 2nd fill & draw experiments were dried at 103 °C for 3
hours to measure the MLSS. Liquid phases were extracted using solid phase extraction (Oasis HLB
20cc cartridge, Waters, USA) following the US EPA method 1694 and eluted in distilled methanol.
Eluates were dried by high purity nitrogen gas and preserved in dark at -20 °C. Prior to yeast
bioluminescence assay, extracts were re-dissolved in 0.75mL distilled methanol (40X
concentrates).
TAS and MBR wastewater effluent sampling and extraction
Field wastewater effluents from TAS and MBR at Hallsdale-Powell wastewater facility were
sampled weekly from June 2011 for the first 14 weeks and then sampled less frequently until
June 2012, spanning 12 months with a total of 31 sampling dates (Table 2.2). Wastewater
effluents treated by TAS and MBR were collected separately in pre-baked (500 °C for 4 hours)
bottles and transported in icebox. Each time 1 L of MBR and TAS effluents were extracted and
tested except for the last three sampling dates, effluents were sampled and tested in triplicate
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Table 2.1. Parameters for lab-scale fill & draw batch reactor experiments
Experiment 1 (TAS biomass)

Experiment 2 (MBR
biomass)

Biomass Sampling
Date

May 2011

July 2011

Total Suspended
Solid

~2500 mg/L

~8500 mg/L

Spiked Estrogen (final
E2 (27.24 mg/L), EE2 (2.96 mg/L)
concentration)

E2 (272.38 mg/L),

Spiked
Androgen(final
concentration)

DHT (29.04 mg/L)

DHT (290.44 mg/L)

Sample Collection
Time

0, 1, 3, 7 day

0, 1, 2, 3, 7 day
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Fig 2.1. Schematic of fill & draw experiment. Three groups of 100 mL bioreactors including (1)
activated sludge (AS), (2) activated sludge with spiked hormones (AS+), (3) filtered raw
wastewater (-control) were maintained at 28 °C, 200 rpm. The Fill & Draw operations were
conducted continuously for 7 days. In each day 30 mL mixed liquid samples were taken out of
each bioreactor and re-filled with filter sterilized raw wastewater (group 2 were also spiked with
hormones). Water samples were concentrated by solid phase extraction and tested by yeast
bioluminescent assay.
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to evaluate the variation in effluents from the same day. All water samples were extracted within
8 hours after sampling using modified US EPA Method 1694. Briefly, solid phase extraction disk
(Oasis HLB disk, Waters, USA) was pre-soaked with 5 mL methanol for 5 min and then conditioned
with 10 mL methanol followed by 10 mL distilled water with vacuum. Then 1 L water sample was
acidified to pH 2.0 ± 0.5 with HCl and passed through the disk at < 40 mL/min under vacuum.
After 15 min of air drying under vacuum, the SPE disk was soaked in 5 mL methanol for 2 min and
eluted under vacuum. Then another elution was performed with 6 mL of 50:50 MeOH/Acetone
and the collected eluate was dried by high purity nitrogen flow and stored at -20 °C. Extracts were
re-dissolved in 1 mL distilled methanol prior to yeast bioluminescent assay (1000X concentrates).
To evaluate the recovery efficiency of the sample extraction method, a triplicate of 1L distilled
water with 2×10-5 mole of spiked E2 and DHT were concentrated using the same *procedure for
wastewater samples. The concentration of recovered E2 and DHT was determined by HP 6890
Gas Chromatography with HP 5973 Mass Spectrometer in Selected Ion Monitoring (SIM)
acquisition mode. Deca-Cl-Biphenyl was used as the internal standard and helium was the carrier
gas. Phenomenex ZB-50 GC column with 250 °C initial temperature and 1.0 mL/min initial flow
was used for E2 detection. Agilent J&W DB-5ms GC Column with 260 °C initial temperature and
1.0 mL/min initial flow was used for DHT detection.
Yeast bioluminescence bioreporter assay (BLYES, BLYAS, BLYR)
Bioluminescent Saccharomyces cerevisiae BLYES (estrogen reporter), BLYAS (androgen reporter),
BLYR (cytotoxicity reporter) (Sanseverino et al. 2009) were inoculated from -80 °C freezer stocks
and grown in modified yeast minimal medium without leucine and uracil (YMM leu-,
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ura-)(Routledge and Sumpter 1996) overnight at 28 °C, 200 rpm to reach OD 0.8 to 1.0 prior to
sample testing.
Concentrated fill & draw experiment samples (40X) were serial diluted in distilled methanol to
12 dilutions ranging from 40X to 0.01X fold to the original sample. Concentrated wastewater
effluent water samples (1000x) were serial diluted to 12 dilutions ranging from 1000X to 2.5X
fold. 50 µL diluted samples were placed into the appropriate wells of Costar 96-well black plates
(#3915 by Corning, Inc. USA) as mapped in Fig. 2.2A. On each plate, serial diluted E2 (1E-6 M to
2.5E-12 M) or DHT (1E-5 M to 2.5E-11 M) in distilled methanol were used as standard chemicals
and

positive

controls

for

BLYES

and

BLYAS

assay

respectively.

Solvent

blanks

(cell+medium+solvent) and true blanks (cell+medium) were included as negative controls.
Loaded 96 wells plates were kept in room temperature to allow the solvent methanol evaporate
and dry-out. Then 200 µL of yeast culture was added into each well of the 96 well plates. Each
sample was tested by BLYES, BLYAS and BLYR to evaluate estrogenicity, androgenicity and
cytotoxicity respectively. Bioluminescence was measured after 4 hours of sample exposure in a
Perkin-Elmer Victor2 Multilabel Counter with an integration time of 1 s/well.
Data Analysis
Bioluminescence (counts per second) readings were plotted against the log of its concentrations
(M), generating sigmoidal curves for estrogen (BLYES) and androgen (BLYAS) assays (Fig. 2.2CD).
The concentration used for water samples were the concentration factors. For standards
(E2/DHT), half maximal effective concentration (EC50) was determined at the mid-point
bioluminescence ((max-min)/2 + min) on the linear portion of the sigmoidal curve (Fig. 2.3a). For
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Table 2.2. Estrogenic Equivalent and Cytotoxicity of TAS and MBR effluent samples
Sampling Date

EEQ50 TAS
(ng/L)

EEQ50 MBR
(ng/L)

EEQ20 TAS
(ng/L)

EEQ20 MBR
(ng/L)

LDC
TAS

LDC
MBR

IC20
TAS

IC20
MBR

6/29/2011

Week 1

4.59E+00

2.39E-01

3.78E+00

2.98E-01

2.5

25

44.59

55.46

7/6/2011

Week 2

9.26E+00

2.08E+00

8.60E+00

2.28E+00

1.25

6.25

52.71

57.34

7/13/2011

Week 3

5.03E+00

3.09E-02

4.43E+00

8.68E-02

2.5

62.5

38.41

64.69

7/20/2011

Week 4

6.82E+00

2.88E+00

5.63E+00

2.49E+00

1.25

2.5

33.72

42.73

7/27/2011

Week 5

5.74E+00

3.67E-01

5.36E+00

1.20E-01

1.25

6.25

28.47

35.55

8/3/2011

Week 6

2.68E+00

2.81E-01

2.96E+00

5.73E-01

6.25

6.25

60.06

71.12

8/10/2011

Week 7

3.81E+00

3.57E-01

2.99E+00

5.62E-01

6.25

12.5

55.09

127.79

8/17/2011

Week 8

7.21E+00

2.65E-01

5.79E+00

4.72E-01

1.25

1.25

33.17

109.20

8/24/2011

Week 9

6.34E+00

3.37E-01

5.36E+00

4.74E-01

1.25

6.25

51.94

186.84

8/31/2011

Week 10

2.16E+01

4.53E-01

1.94E+01

4.54E-01

0.625

12.5

22.21

45.35

9/7/2011

Week 11

2.82E+00

3.55E-01

2.30E+00

4.31E-01

6.25

25

40.82

32.86

9/14/2011

Week 12

1.37E+00

6.46E-02

1.55E+00

1.29E-01

6.25

25

55.48

44.11

9/21/2011

Week 13

8.40E-01

1.04E-02

1.14E+00

3.60E-02

12.5

62.5

38.95

72.57

9/28/2011

Week 14

6.57E+00

4.30E-01

5.80E+00

4.23E-01

6.25

62.5

23.98

74.41

10/12/2011

Week 16

4.14E-01

7.42E-02

5.23E-01

1.11E-01

12.5

62.5

20.24

77.07

10/26/2011

Week 18

1.67E-01

2.40E-02

3.01E-01

4.19E-02

12.5

62.5

36.10

79.91

11/9/2011

Week 20

7.49E-01

4.42E-03

7.81E-01

1.98E-02

12.5

62.5

34.78

51.33

11/23/2011

Week 22

2.33E+00

3.30E-01

2.44E+00

2.81E-01

2.5

62.5

43.08

72.66

12/15/2011

Week 25

3.36E+00

1.65E-01

3.03E+00

1.75E-01

2.5

62.5

49.15

106.50

12/29/2011

Week 27

3.90E+00

1.84E-02

3.81E+00

4.56E-02

1.25

1.25

38.55

194.93

1/12/2012

Week 29

2.62E-01

3.92E-03

6.70E-01

9.34E-03

6.25

250

86.31

90.28

2/3/2011

Week 33

2.75E+00

2.22E-02

4.06E+00

3.00E-02

2.5

25

69.58

102.98

2/17/2011

Week 35

2.97E-02

3.22E-03

1.68E-01

3.25E-02

6.25

25

55.76

86.14

3/9/2012

Week 38

1.82E+00

6.56E-02

2.99E+00

3.69E-02

6.25

125

23.26

67.93

4/5/2012

Week 42

3.82E-05

nd

1.70E-03

nd

25

nd

19.73

17.28

4/25/2012

Week 45

3.04E-02

nd

1.33E-01

nd

12.5

nd

21.64

5.32

5/3/2012

Week 46

1.03E-01

2.13E-03

7.03E-01

2.24E-02

2.5

25

20.42

18.96

6/6/2012

Week 51

7.15E-02

2.36E-03

2.54E-01

2.86E-02

6.25

25

7.41

1.23

6/13/2012

Week 52

1.13E-02

1.34E-05

5.90E-02

4.58E-04

(±1.96E-03)

(±1.19E-05)

(±5.77E-03)

(±3.29E-04)

12.5

62.5

6.78

5.59

6/20/2012

Week 53

1.71E-02

2.33E-05

7.39E-02

6.42E-04

(±1.33E-02)

(±1.88E-05)

(±2.90E-02)

(±4.59E-04)

12.5

62.5

2.93

2.41

6/26/2012

Week 54

nd

62.5

nd

2.05

1.15

3.89E-04
(±5.36E-04)

nd

3.29E-03
(±3.99E-03)

Average

3.25

0.32

3.07

0.35

8.21

43.93

36.05

64.57

Std Dev

4.33

0.64

3.79

0.61

11.46

50.19

19.74

48.16

Nd: non-detectable
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Table 2.2 Continued
EEQ50: estrogenic equivalents calculated by EC50 of 17β-estradiol and samples
EEQ20: estrogenic equivalents calculated by EC20 of 17β-estradiol and samples
LDC: lowest detectable concentration. The lowest concentration factor of tested sample that
produces significant bioluminescence response (> 3 standard deviations of background) in BLYES
assay.
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Fig.2.2 Schematic of wastewater sample testing by S. cerevisiae BLYR, BLYES, and BLYAS on 96
well plates. (a). 96 well plate map for sample testing. In sample testing, each plate includes a serial diluted
standard estrogen/androgen (E2 or DHT) to provide reference for sample estrogenicity and androgenicity
estimation, as well as positive controls. Solvent blanks (methanol + cell culture) and true blanks (cell
culture) are included as negative controls. In this layout, 6 serial diluted wastewater samples can be tested
on each plate. Each sample is tested by BLYR, BLYES and BLYR on three separated plates respectively. (b).
Bioluminescence production of S. cerevisiae BLYES after 4 hours exposure to standard E2 and wastewater
samples on 96 well plate, captured by Xenogen IVIS Lumina Imaging System. Higher level of luminescence
indicates stronger estrogenic response. (c). Standard dose-response curves of S. cerevisiae BLYR, BLYES
and BLYAS after exposure to the E2 and DHT. Bioluminescence readings in the unit of counts per second
(CPS) are plotted against log concentrations of the standard chemical. Constitutive light producing BLYR
strain serves to monitor sample toxicity; a flat curve indicates no detectable cytotoxicity. BLYES and BLYAS
produce sigmoidal curves upon exposure to E2 and DHT respectively. EC50 value for E2 and DHT can be
calculated from the sigmoidal dose-response curves. (d). Wastewater sample (first week TAS and MBR
effluent) testing results by S. cerevisiae BLYR, BLYES and BLYAS. Bioluminescence readings were plotted
against log concentration factor of samples. The drop of BLYR curves at higher concentration indicate the
presence of cytotoxicity in these sample dilutions.
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Fig.2.3 Comparative data analysis for yeast bioluminescent assays effective concentration calculation. (a) EC50 and EC20 calculation
for standard chemical 17β-estradiol. (b) IC20, EC20, EC50 calculation for wastewater samples. (EC50 = half-maximal effective
concentration, EC20 = 20%-maximal effective concentration, IC20 = 20%-maximal inhibitory concentration)
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environmental samples, the concentration factor that yields half maximal bioluminescent
response was used as the EC50 (Fig. 3b). Due to the cytotoxicity in concentrated environmental
samples, sample testing may not be able to produce a full sigmoidal curve. Therefore linear
regression was applied on the linear portion of data points and the obtained linear equation was
used to calculate sample’s EC50 using the half-maximal bioluminescence value obtained from the
corresponding E2/DHT standard curve in the same batch of experiment. In all sample testing, a
response was considered significant when the bioluminescence increase is higher than three
times of the background bioluminescence standard deviation. Estrogenic equivalent (EEQ) and
androgenic equivalent (AEQ) were calculated by using the EC50 of E2/DHT divided by the EC50 of
each sample from the same batch of experiment. EEQ and AEQ represent the amount of
hormonal active substances in the samples relative to E2/DHT. For wastewater effluents samples,
EEQ was also calculated through the EC20 (20% maximal effective concentration) of the sample
and standard, and was denoted as EEQ20. To differentiate, EEQ calculated using EC50 was
denoted EEQ50 in the result section. Cytotoxicity of wastewater samples tested by S. cerevisiae
BLYR was reported as the concentration factor where 20% of bioluminescence inhibition (IC20)
occurred. To calculate IC20, the data points showing inhibition were fitted with linear regression
and the IC20 was inferred from the linear equation at 80% of the background bioluminescence.

2.3 Results and Discussion
E2 and DHT recovery efficiency by solid phase extraction
To evaluate the recovery efficiency of the wastewater extraction method, GC-MS was used to
measure the recovery of natural estrogen (E2) and androgen (DHT) from spiked distilled water
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(Table 2.3). E2 was determined to be an average of 4.45 ppm with 5.19% CV, and the recovery
rate was averaging 81.71%. An average of 3.49 ppm DHT were detected in the concentrated
sample with 46.27% coefficient of variation (CV), and an average of 60.05% recovery rate. The
recovery rate for E2 and DHT were comparable to the recovery of tested chemicals in EPA’s 1694
method report, though the CV of DHT recovery was slightly larger.
Total estrogenic and androgenic activity changes in fill & draw bioreactors
Lab-scale fill & draw bioreactors were used to simulate the removal process in wastewater
treatment plant. The total estrogenicity, androgenicity and cytotoxicity in the effluent of fill &
draw bioreactors were tested by S. cerevisiae BLYES, BLYAS and BLYR respectively. Fig 2.4
presents the plots of test results for the unspiked, spiked and negative control reactors from the
two separate experiments. Calculated estrogenic equivalents and androgenic equivalents are
presented in Table 2.4.
In the 1st fill & draw experiments (TAS), unspiked AS samples showed no detectable estrogenic
response across all time points. The negative controls, which contained the filtered raw
wastewater, showed weak response with average EEQ of 0.11, 0.02 and 0.04 ng/L at 0, 24 and
72 h respectively, validating the presence of estrogenic compounds in the raw wastewater. No
estrogenic response were detected at 168 h, which may be due to an error in the last refill
operation that yeast minimal media was mistakenly added into the reactors. In comparison, the
spiked TAS bioreactor samples showed very strong estrogenic responses at time 0 due to spiked
E2 and EE2. The calculated EEQ at time 0 was averaging 332.66 ng/L. At 24 hour, estrogenic
response significantly decreased, and the EEQ reduced to an average of 1.64 ng/L. At 72 hours
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Table 2.3. Recovery rate of natural estrogen and androgen using modified EPA 1694 method for
water sample extraction
Sample Name

Dihydrotestosterone
(DHT)
17β-estradiol (E2)

Sample Mean
Concentration
(ppm)
3.49

Coefficient of
Variation

4.45

52

46.27%

Spiked
Concentration
(ppm)
5.80

Average
Recovery
Rate
60.05%

5.19%

5.45

81.71%

Table 2.4. Estrogenic and Androgenic Equivalents of Fill & Draw Bioreactors Effluent
Experiment 1 (TAS biomass)
EEQ (ng/L)
Time

AS

AS+
332.66
(±182.1
2)
1.64
(±0.88)

Experiment 2 (MBR biomass)

AEQ (ng/L)

EEQ (ng/L)

AEQ (ng/L)

-Ctrl

AS

AS+

-Ctrl

AS

AS+

-Ctrl

AS

AS+

-Ctrl

0.11
(±0.09)

nd

896.17
(±325.60)

53.93
(±25.25)

0.01
(±0.01)

5433.70
(±372.8)

29.83
(±1.52)

nd

500.57
(±138.46)

320.86
(±46.01)

0.02
(±0.01)

nd

nd

36.00
(±5.03)

0.07
(±0.11)

1.06 (±0.82)

nd

nd

nd

nd

nd

nd

nd

nd

0h

nd

24 h

nd

48 h

-

-

-

-

-

-

nd

nd

72 h

nd

nd

0.04
(±0.02)

nd

nd

22.04
(±11.70)

nd

nd

168 h

nd

nd

nd

nd

nd

nd

nd

0.32±0.51

Mean ± SD.
nd: non-detectable.
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17.79
(±0.76)
18.98
(±0.65)
13.36
(±8.11)
8.56
(±1.33)

195.44
(±8.73)
146.49
(±29.80)
207.96
(±59.75)
345.19
(±117.00)

Fig.2.4 Time course analysis of bioluminescent yeast endocrine disruptor screening of lab-scale
fill & draw wastewater treatment effluents. Experiment 1 used the activated sludge biomass from
TAS, experiment 2 used the biomass from MBR (see also Table 2.1). In each plot, Y axis represents
logged bioluminescence readings, X axis represents logged sample concentrations (from low to
high). The point curve on the upper side was obtained from Saccharomyces cerevisiae BLYR for
monitoring sample toxicity. Reduced bioluminescence in BLYR assay at higher concentration
indicates the presence of cytotoxicity. The point curve on the lower side was obtained from
Saccharomyces cerevisiae BLYES or BLYAS strain for detecting the presence of estrogenic or
androgenic compounds, respectively.
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and 168 hours, no estrogenic responses were detectable. Considering the rapid removal of
estrogenic response in the first experiments and the higher MLSS in MBR as compared to TAS
(8500 mg/L vs. 2500 mg/L), in the 2nd fill & draw experiments, 10 times higher concentration of
E2 (1 mM) was spiked and an additional sampling time at 48 h was added. The estrogenic activity
of the filtered raw wastewater in the second experiment was much higher than the first
experiment; the EEQ of the negative control at time 0 averaged 29.83 ng/L in the second
experiment compared to 0.11 ng/L in the first experiment. As a result, the EEQ at time 0 in the
spiked MBR bioreactors was significantly higher than that of the spiked TAS bioreactors at this
time point (5433.70±372.8 ng/L vs. 332.66±182.12 ng/L, Table 2.4). Despite higher input of
hormonal compounds, MBR biomass demonstrated very high efficiency in removing estrogenic
activities. At 24 hour, the EEQ in spiked MBR bioreactors decreased to 1.06±0.82 ng/L. At 48 and
72 hours, no response was detectable in spiked MBR bioreactor effluent. However, at 168 hours,
light response was detected, which could be the result of reduced biomass concentrations, as
MLSS in the spiked MBR reactors decreased from 8666 mg/L to 666 mg/L after 7 days of fill &
draw operations (Fig. 2.5).
Androgenic activities were detected in the negative controls (filtered raw wastewater) in both
experimental groups. In the first experiments, initial AEQ averaged 0.11 ng/L while in the second
experiments, initial AEQ averaged much higher at 320.86 ng/L. Both TAS and MBR biomass
successfully removed the androgenic compounds in the filtered raw wastewater to below
detectable level, as no androgenic activities were detected in the unspiked bioreactors in both
groups of experiments throughout all the time points. Moreover, although strong androgenic
response was detected at time 0 in both spiked TAS and MBR bioreactors due to spiked DHT, no
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Fig 2.5. Mixed liquor suspended solid (MLSS) in spiked MBR bioreactors at 0, 1, 2, 3 and 7 day.
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androgenic activates were detected after 24 hours in both experiments. Despite of 10 fold higher
level of spiked DHT into the MBR bioreactors, the AEQ at time 0 (500.57±138.46 ng/L) wasn’t
higher than that of the spiked TAS bioreactor (896.17±325.60 ng/L) at this time point, suggesting
a strong initial adsorption to the solid phase occurred. As the sampled MBR activated sludge had
over 3 times higher TSS concentration than that of the TAS, this may explain why the initial AEQ
in the spiked MBR reactors was not higher than that of the TAS reactors.
At the beginning of both experimental conditions, high concentration of estrogen and androgen
were spiked into the bioreactors. Although the samples at time 0 were obtained immediately
after the spike, the EEQ and AEQ in the spiked reactors at time 0 were significantly less than the
spiked concentration, suggesting a rapid removal of hormones from the water phase occurred.
This rapid removal was likely the result of adsorption to the biosolid, as two previous studies
using activated sludge lab bioreactor also showed that the majority of spiked E2 and EE2 were
instantly removed from water phase to solid phase by adsorption (Hashimoto and Murakami
2009; Suzuki and Maruyama 2006). During the 2nd fill & draw experiments, MLSS in the spiked
bioreactors were measured (Fig. 2.5). The MLSS at the beginning of the experiment averaged
8666.6 mg/L, and continuously decreased along with the fill & draw operation each day, reaching
an average of 666.6 mg/L by the end of the experiment. Despite the significant decrease of MLSS,
the ability of the activated sludge in removing estrogenic and androgenic compounds was
scarcely affected. Considering the high level of hormones added, it is likely that the microbial
community adapted to the degradation of spiked hormones.
In the fill & draw bioreactor experiments, using filter sterilized raw wastewater as the refill
allowed the activated sludge biomass to receive the same influent as in the field, which contains
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complex organic contents including hormonal active compounds. Spiking E2, EE2 and DHT along
with the filtered raw wastewater simulated the sudden increase of estrogenic and androgenic
compounds in the wastewater and challenged the yeast bioluminescence reporters’ ability to
detect the change of hormonal activities in the samples. Overall, yeast reporters successfully
detected the decrease of total endocrine disruptive activity in the treated wastewater during the
fill & draw experiment. Coupled with the modified EPA 1694 sample prep method, yeast
bioreporters produced monitoring results with good reproducibility (CV ranged from 3% to 172%)
in 4 hours of sample exposure, proving their suitability to rapidly and effectively gauge the level
of endocrine activities in wastewater samples.
Total androgenic, estrogenic activities and cytotoxicity in MBR and TAS wastewater effluents
at HPUD
MBR and TAS effluent samples from week 1 to 27 were tested by BLYAS for androgenic responses.
However BLYAS assay didn’t detect any significant androgenic response in all effluent samples,
suggesting that androgenic compounds in both MBR and TAS effluents were consistently at
below detection level. Therefore BLYAS assay was excluded for the effluent samples after the
27th week. The undetectable level of androgenic compounds in both MBR and TAS effluent was
also in agreement with our findings in the fill & draw experiments, in which high level of spiked
DHT in both MBR and TAS activated sludge were quickly removed within 24 hours and the level
of androgenic compounds remained below detection level throughout the 7 days experiment
period.
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Estrogenic equivalents data for both TAS and MBR effluent field sample are presented in Fig. 2.6.
All MBR and TAS effluent samples from June, 2011 to June 2012 was evaluated by BLYR and BLYES
assay respectively for cytotoxicity and estrogenic activities The calculated estrogenic equivalents,
lowest detectable concentration (LDC) and IC20 are listed in Table 2.2. In our study, all wastewater
samples demonstrated various level of cytotoxicity. The IC20 of MBR effluent ranged from 1.15 to
194.94, and averaged 64.57. In comparison, the IC20 of TAS effluent ranged from 2.05 to 85.31
with an average of 36.05, indicating higher overall toxicity than MBR effluent. The IC20 of MBR
and TAS had moderate correlation of 0.58 (Table 2.5), suggesting the variation of influent toxicity
was one of the key contributing factors for effluent toxicity level. When comparing MBR with TAS
in each individual day, the toxicity of MBR effluent was lower than that of TAS effluent on 22 of
the 31 sampling dates, suggesting that MBR in general can achieve better cytotoxicity removal.
All TAS effluent samples showed estrogenic responses in BLYES assay throughout the 12 months
of monitoring (Fig. 2.6, Table 2.2). The calculated EEQ50 for TAS effluent ranged from 21.61 ng/L
to 0.04 pg/L, with an average of 3.25 ng/L and 4.33 ng/L SD. Most MBR effluent samples showed
detectable estrogenic responses in BLYES assay except 3 of the 31 sampling dates. Compared to
TAS, the calculated EEQ50 for MBR effluent ranged from 2.88 ng/L to 0.0134 pg/L, with
approximately an order of magnitude lower average of 0.32 ng/L and 0.64 ng/L SD. The level of
effluent EEQ in our study agrees with the results in several previous investigations conducted in
different countries(Holbrook et al. 2002; Kirk et al. 2002; Murk et al. 2002; Svenson et al. 2003;
Tanaka et al. 2001; Vethaak et al. 2005). In these studies, bioassays including YES, E-screen and
ER-CALUX were used and the estimated WWTP effluents EEQ varied from <0.1 to 29.8 ng/L.
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1e+2

Estrogenic Equivalent (log ng/L)

1e+1
1e+0
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Fig 2.6. Estrogenic equivalent (EEQ50) of TAS and MBR effluent from all field sampling dates. (see
also Table 2.2).
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Table 2.5. Pearson’s correlation coefficient between effluent EEQ and key WWTP operational parameters.
EEQ50
TAS
(ng/L)

TAS
EEQ50
removal

EEQ50
MBR
(ng/L)

MBR
EEQ50
removal

EEQ20
TAS
(ng/L)

TAS
EEQ20
removal

EEQ20
MBR
(ng/L)

MBR
EEQ20
removal

LDC
TAS

LDC
MBR

IC20
TAS

IC20
MBR

EEQ50 TAS (ng/L)
TAS EEQ50 removal

-1.00**

EEQ50 MBR (ng/L)

0.42*

-0.42*

MBR EEQ50 removal

-0.44*

0.44*

-1.00**

EEQ20 TAS (ng/L)

0.99**

-0.99**

0.39*

TAS EEQ20 removal

-0.99**

0.99**

-0.39*

0.42*

-1.00**

EEQ20 MBR (ng/L)

0.43*

-0.43*

0.98**

-0.98**

0.41*

-0.41*

MBR EEQ20 removal

-0.46**

0.46**

-0.98**

0.98**

-0.43*

0.43*

-1.00**

-0.42*

LDC TAS

-0.38*

0.38*

-0.38*

0.25

-0.40*

0.40*

-0.39*

0.26*

LDC MBR

-0.35

0.35

-0.30

0.30

-0.33

0.33

-0.34

0.34

0.36

IC20 TAS

0.07

-0.07

0.06

-0.11

0.09

-0.09

0.12

-0.18

-0.44*

0.21

IC20 MBR

0.20

-0.20

-0.09

0.02

0.20

-0.20

-0.03

-0.04

-0.40*

-0.07

0.58**

TAS MLSS (mg/L)

-0.09

0.09

-0.27

0.27

-0.03

0.03

-0.25

0.26

0.10

0.15

-0.04

0.07

TAS MLVSS (mg/L)

-0.13

0.13

-0.34

0.34

-0.07

0.07

-0.33

0.33

0.10

0.18

-0.07

0.10

TAS SRT (day)

-0.03

0.03

-0.25

0.25

0.02

-0.02

-0.26

0.25

0.06

-0.05

0.06

0.11

TAS HRT (hour)

0.24

-0.24

-0.01

0.02

0.20

-0.20

0.05

-0.03

0.28

-0.25

-0.38*

-0.18

TAS F/M Ratio

-0.04

0.04

0.28

-0.29

-0.07

0.07

0.26

-0.26

-0.15

0.11

0.18

-0.04

MBR MLSS (mg/L)

-0.30

0.30

-0.22

0.22

-0.31

0.31

-0.20

0.21

0.10

0.08

-0.08

-0.01

MBR MLVSS (mg/L)

-0.31

0.31

-0.25

0.25

-0.33

0.33

-0.24

0.24

0.10

0.13

-0.07

0.04

MBR SRT (day)

-0.02

0.02

-0.07

0.06

0.02

-0.02

-0.13

0.12

-0.16

-0.11

0.16

0.31

MBR HRT (hr)

0.07

-0.07

0.25

-0.22

0.02

-0.02

0.22

-0.19

0.17

-0.16

-0.27

-0.09

MBR F/M Ratio

0.10

-0.10

-0.14

0.14

0.08

-0.08

-0.08

0.08

0.05

-0.05

-0.08

-0.04

RAIN (inches per 24hr)

-0.24

0.24

-0.15

0.15

-0.20

0.20

-0.18

0.18

-0.04

0.77**

0.20

0.00

TREATED PLANT INFLUENT (MGD)

-0.16

0.16

-0.11

0.09

-0.11

0.11

-0.15

0.12

-0.19

0.31

0.38*

0.22

TOTAL PLANT EFFLUENT (MGD)

-0.14

0.14

-0.11

0.09

-0.09

0.09

-0.15

0.12

-0.20

0.35

0.36*

0.21

EFFLUENT TEMP. (CELSIUS)

0.34

-0.34

0.27

-0.26

0.27

-0.27

0.31

-0.30

0.13

-0.47**

-0.37*

-0.28
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Table 2.5. Continued
EEQ50
TAS
(ng/L)

TAS
EEQ50
removal

EEQ50
MBR
(ng/L)

MBR
EEQ50
removal

EEQ20
TAS
(ng/L)

TAS
EEQ20
removal

EEQ20
MBR
(ng/L)

MBR
EEQ20
removal

cBOD5 Plant Influent (mg/L)

0.26

cBOD5 Plant Effluent (mg/L)

0.04

-0.26

0.34

-0.33

0.21

-0.21

0.39*

-0.38*

0.08

-0.21

-0.22

-0.16

-0.04

-0.31

0.23

0.04

-0.04

-0.28

0.20

-0.19

0.38*

0.38*

0.36*

LDC
TAS

LDC
MBR

IC20
TAS

IC20
MBR

Suspended Solid Plant Influent (mg/L)

0.15

-0.15

0.40*

-0.40*

0.09

-0.09

0.43*

-0.43*

0.00

-0.22

-0.15

-0.21

Suspended Solid Plant Effluent (mg/L)

-0.20

0.20

-0.15

0.13

-0.18

0.18

-0.17

0.14

-0.06

0.39*

0.31

0.09

Settled Solid Plant Influent (mL/L)

0.19

-0.19

0.43*

-0.43*

0.13

-0.13

0.46*

-0.46**

-0.03

-0.24

-0.14

-0.18

Dissolved Oxygen Plant Influent (mg/L)

-0.48**

0.48**

-0.39*

0.38*

-0.44*

0.44*

-0.43*

0.41**

0.06

0.57**

0.22

0.22

Dissolved Oxygen Plant Effluent (mg/L)

-0.27

0.27

-0.37

0.37

-0.23

0.23

-0.40*

0.40*

0.01

0.59**

0.29

0.09

Ammonia Plant Influent (mg/L)

0.12

-0.12

0.05

-0.03

0.10

-0.10

0.07

-0.04

0.27

-0.08

-0.49**

-0.23

Ammonia Plant Effluent (mg/L)

0.79**

-0.79**

0.04

-0.05

0.80**

-0.80**

0.03

-0.04

-0.12

-0.12

-0.13

-0.07

* Significant at p < 0.05; ** Significant at p < 0.01;
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When comparing the EEQ50 of MBR and TAS effluent on each sampling date (Fig. 2.6), the MBR
at HPUD consistently produced effluent with less estrogenic activity than the TAS throughout the
monitoring period. The average estrogenic equivalent from MBR effluent was about 10 times less
than that of TAS. Several previous studies featuring either lab-scale or full-scale MBR and TAS on
different locations also suggested that MBR can deliver enhanced removal performance for
several different type of EDCs (Clara et al. 2005b; Gaulke et al. 2009; Radjenović et al. 2009; VegaMorales et al. 2013). The findings in our study add further evidence that MBR is more effective
in EDCs removal, and the conclusion is based on the long-term 12 months monitoring on fullscale TAS and MBR operating in parallel with the same source of influent.
In order to evaluate the variation of EDCs level in wastewater effluent, in the last three sampling
dates (week 52 to 54), triplicate sampling, extraction and assay were performed on the MBR and
TAS effluents. The coefficient of variation (CV) for TAS EEQ50 was calculated as 17%, 78% and 138%
for week 52, 53 and 54 respectively. While the CV for MBR EEQ50 were 89% and 81% for the
detectable week 52 and 53 respectively. These results demonstrated that our wastewater
extraction and yeast assay protocol has relatively small variation when testing field wastewater
sample, and is able to gauge and differentiate hormonal activities changes at least on the
magnitude level.
EEQ is a well-recognized metric to describe the level of estrogenic activity for a certain chemical
or sample. Generally EEQ is obtained by dividing the EC50 of 17β-estradiol with the EC50 of the
sample. However when calculating EEQ for environmental samples, special care should be taken
as cytotoxicity in the samples could greatly influence the end result. In our study, although
wastewater samples were concentrated 1000 times, most samples showed significant response
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in BLYES assay without producing a full sigmoidal curve. Therefore in sample EC50 calculation, we
used the max and min bioluminescence of the 17β-estradiol response curve instead of the sample
to identify the half-maximal response value. Then the fitted linear equation of the responsive
sample data points was used to extrapolate the EC50. A potential drawback of this calculation is
that when the sample contains high cytotoxicity, bioluminescence response at high
concentration is inhibited, which yields smaller slope in the fitted linear equation, causing
overestimated EC50 and underestimated EEQ. This bias becomes more prominent when sample
has weaker estrogenicity. To address this problem, an alternative way of EEQ calculation is to use
the EC20 of the sample and 17β-estradiol instead of the EC50. In theory, reduced slope has less
impact on EC20 than EC50 (see Fig. 2.3). Therefore EEQ calculation based on EC20 could help
alleviate the bias caused by sample toxicity. To compare these two calculations, we calculated
the EEQ for all the effluent samples using both EC50 and EC20, and named them as EEQ50 and EEQ20
respectively. EEQ20 showed nearly identical trend as EEQ50. The correlation between the EEQ50
and EEQ20 for TAS and MBR was 0.99 and 0.98 respectively (Table 2.5). As expected, the main
differences between EEQ50 and EEQ20 lie in samples with low estrogenic activities (Table 2.2 and
Fig. 2.7). For both MBR and TAS samples, EC20 based calculation significantly elevated the EEQ
values for weak estrogenic samples. The minimum, lower quartile and media values of TAS EEQ
all increased when calculated by EC20 (Table 2.6). Stronger trend was seen in the EEQ of MBR
effluents as they contained less estrogenic activities. The distribution of MBR samples showed
increased values between 0.5 and 1 in EEQ20. The minimum EEQ of TAS effluent increased by
2989% from 3.82×10-5 to 1.18×10-3 ng/L while the minimum EEQ of MBR increased by 2810%
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Fig 2.7. Distribution and boxplot for EEQ50 and EEQ20 of MBR and TAS effluent
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Table 2.6. Descriptive statistics for EEQ50 and EEQ20 of MBR and TAS field effluent samples
EEQ50 TAS

EEQ20 TAS

EEQ50 MBR

EEQ20 TAS

(ng/L)

(ng/L)

(ng/L)

(ng/L)

Maximum

21.61

19.38

2.88

2.49

75% percentile

5.03

4.43

0.35

0.45

median

2.33

2.44

0.07

0.12

25% percentile

0.10

0.30

0.01

0.03

minimum

3.82E-05

1.18E-03

1.34E-05

3.90E-04

Mean

3.25

3.07

0.32

0.35

Std. Dev

4.33

3.80

0.64

0.61
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from 1.34×10-5 to 3.90×10-4 ng/L. These findings suggest that EC20 based EEQ may to be more
suitable for describing the estrogenic activity in toxic environmental samples.
It’s worth noting that EEQ calculation for wastewater samples was based on the assumption that
there were no cytotoxicity or inhibitory compounds present, and the sample can be further
concentrated to allow the estrogenic response of the in vitro assay reach the same maximum
level as 17β-estradiol. In actual wastewater samples, these assumptions are unlikely to be true,
since toxic, antagonistic or synergistic effects could all be present. Therefore when interpreting
EEQ/AEQ from in vitro assays, it is necessary to understand that the measurement is reflecting a
combined effect. The link between bioassay and chemical analysis in WWTP EDCs detection were
discussed by many researchers. While some studies found natural estrogens E1, E2, E3 and
synthetic estrogen EE2 detected in chemical analysis can account to up to 98% of estrogenic
activities determined in yeast or mammalian cell based bioassays, some also found over or under
representation of estrogenicity by compounds identified in targeted-detection(Liu et al. 2009). A
previous study also found that androgenic activity detected by yeast based androgen assay could
not be fully explained by the compounds detected in chemical analysis(Drewes et al. 2006). These
studies suggest that chemical analysis alone isn’t sufficient to comprehensively evaluate the
hormonal activity in wastewater samples. A previous study conducted receiver operating
characteristic analysis to assess the sensitivity and specificity of in vitro assays including YES,
human reporter gene assay and e-screen for estrogenic compound detection and concluded that
all evaluated in vitro assays were able to effectively predict the in vivo effects of tested
compounds (Martin et al. 2005). Since the contents of wastewater could differ considerably
across time and geological locations, and the fate of different EDCs can be influenced by many
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factors in wastewater treatment, in vitro bioassay should be incorporated as a routine analysis
for WWTP performance evaluation.
Relationship between Operational Parameters and residual EDCs in effluent
The operational parameters of HPUD wastewater facility on the sampling dates along with the
tested EEQ, IC20 are summarized in Supplemental Table 2.1. Parameters that were monitored
separately for TAS and MBR included MLSS, MLVSS, SRT, HRT and F/M ratio. Other operational
parameters monitored for the influent and effluent of the entire plant included the total flow,
cBOD5, suspended and settled solid, dissolved oxygen and ammonia content. To determine
whether these operational parameters are responsible for the variation of EEQ level in the
effluent, Pearson’s correlation analysis was performed (Table 2.5). MBR and TAS EEQ removal
efficiencies were also included in the correlation analysis. To obtain EEQ removal efficiency, we
assumed a steady state influent EEQ concentration equivalent to 29.82 ng/L, which was
measured on the raw wastewater used the 2nd fill & draw experiments (Supplemental Table 2.1).
No significant correlation was found between effluent EEQ, EEQ removal efficiency and key
operational parameters MLSS, MLVSS, SRT and HRT for either MBR or TAS. Similar findings on the
influence of WWTP operational parameters on EDC removal was discussed in several previous
studies as well. SRT is one of the critical parameters for the bioremoval activity of activated sludge.
One study suggested that the SRT above 10 days can increase the quantity of nitrification bacteria
and provide higher removal of micropullutants including natural estrogens and bisphenol A(Clara
et al. 2005a). While another study found that SRT above 2 days yielded similar high EDCs removal,
and no significant improvement was found with longer SRT(Drewes et al. 2006). A third study
also claimed no statistically significant correlation between EDCs removal and SRT, though they
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did find that WWTPs with either high SRT or nitrification activity were more effective on hormone
removal (Servos et al. 2005). In our study, SRT for TAS and MBR were all above 2 days, and the
majority of dates had high SRT over 10 days. SRT variation above these critical values were found
with minimal impact on the effluent EDCs level. This may explain why no correlations were found
between the estimated effluent EDCs level/removal efficiency and SRT.
HRT is the amount of time wastewater is exposed to the biosolid for biodegradation and
adsorption. In our study, no substantial correlation was found between HRT and effluent EEQ
level/removal efficiency. Previous studies also found no statistically significant correlation
between HRT and EDCs removal efficiency, though they do find that higher HRT can exert positive
effect on EDCs removal (Drewes et al. 2006; Servos et al. 2005).
A previous study reported good correlation between BOD removal and EDCs removal in
secondary treatment(Drewes et al. 2006). In our study, BOD was measured on the combined
effluent rather than separately for MBR and TAS, and we found no correlation between both
estimated EEQ and removal efficiency of MBR/TAS and BOD removal. Although BOD removal was
highly efficient at HPUD (removal rate ranged from 93.3% to 99.5%, averaging 98.3%), various
level of EEQ was still present in the effluent, suggesting that effluent BOD level is not an accurate
indicative index for EDCs level, and dedicated EDCs assay is necessary for more appropriate
estimation.
As the MBR and TAS at HPUD process the same source of wastewater influent, they provided the
unique opportunity for long-term direct field comparison between these two technologies.
Typically MBR technology allows longer SRT and higher MLSS than TAS(Drewes et al. 2006). In
our study, MBR operated at similar average SRT as TAS did, but maintained significantly higher
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MLSS level in all sampling dates. The average MLSS in MBR averaged 5447.7 mg/L, which was
more than two times higher than the average MLSS in TAS (2506.8 mg/L). Despite having lower
average HRT compared to TAS (16.21 vs. 31.10 hrs), MBR effluent still consistently demonstrated
less estrogenic activity and toxicity than TAS. This result is also in line with the findings in our fill
& draw experiments, in which more concentrated MBR biosolid demonstrated faster hormone
removal than TAS biosolid. Although previous studies also suggested that higher MLSS in MBR
contributes to its improved EDCs removal(Drewes et al. 2006; Hu et al. 2007; Judd 2008), whether
this is the sole contributing factor to the ~10 fold difference in effluent estrogenic activity at
HPUD requires further investigation.

2.4 Conclusions
In this study, we demonstrated the use of standardized yeast bioluminescent assays as highthroughput screening tools to monitor the estrogenic, androgenic potencies and toxicity in the
wastewater treatment systems. To evaluate the sensitivity and reproducibility of the yeast assay
in wastewater monitoring, we conducted 7 days semi-continuous batch reactor experiments
using the activated sludge and raw wastewater spiked with hormones. Yeast bioreporter assay
successfully captured the rapid removal of estrogenic and androgenic activities in the bioreactors,
and also demonstrated good reproducibility and sensitivity. This standardized assay was then
applied in a 12 month comparative study on the wastewater effluent from the parallel-operated
MBR and TAS located at Powell, TN, USA. The yeast assay detected no significant androgenic
response in all tested TAS and MBR samples. While all TAS effluent samples and most (3 of the
31 dates) MBR effluent samples showed detectable estrogenic activity. The EEQ50 for TAS effluent
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ranged from 21.61 ng/L to 0.04 pg/L and averaged 3.25 ng/L. For MBR, the effluent EEQ ranged
from 2.88 ng/L to 0.0134 pg/L and averaged ~10 fold less (0.32 ng/L) than TAS. Despite the large
temporal variation, the EEQ level in MBR effluent was consistently lower than that of TAS on any
given sampling day. Most MBR effluent samples also contained less cytotoxicity than TAS. These
data collectively suggest that MBR can significantly reduce the release of EDCs and toxic
compounds into the environment. Further analysis revealed no significant correlation between
effluent EEQ level and WWTP operational parameters including MLSS, SRT, HRT and BOD. Overall,
our study demonstrated that the yeast bioluminescent assay is suitable to serve as a sensitive,
high-throughput, rapid and low-cost EDCs screening tool for routine wastewater monitoring
purpose.
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Chapter 3. Computational Modeling of Interactions between Human
Estrogen Receptor Mutants and Endocrine Disruptors
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Abstract
This chapter describes and reports the results from the computational modelling of the
interaction between selected estrogenic EDCs and wildtype/mutant hERα ligand binding domain.
Five point mutations (Asp351Tyr, Glu353Val, Met396Val, Leu525Ala and Asp538Gly) that are
close or inside hERα ligand binding pocket were selected from previous literature and cancer
database. Two forms of hERα ligand binding domain, the agonist form and antagonist form and
their in silico mutated models were subjected to molecular dynamics (MD) simulation to explore
potential conformation changes in the binding pocket as the result of point mutations . MD
trajectories were clustered based conformation variation and one conformation was chosen
from each of the cluster. Selected MD conformations were computationally docked with 29
selected environmental EDCs to evaluate the changes of predicted binding affinity as the result
of point mutations.

3.1 Introduction
Human estrogen receptor alpha (hERα) features flexible binding pocket that many natural and
artificial ligands besides natural estrogens can also bind and modulate the activation of the
receptor and downstream transcriptional activity. Since these non-natural hormonally active
compounds can directly impact and interfere the normal function of the endocrine system, they
were commonly referred as endocrine disruptive chemicals (EDCs). As the public health concern
of EDCs increased in the past decades, many research efforts were emphasized on the screening
and estimation of EDC potency. These studies mostly focused on evaluating the response of the
most common receptor form, the “wild type” human estrogen receptor, that is defined by
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current understanding of the protein hERα. However in human genome, small genetic variations,
often referred as single nucleotide polymorphism (SNPs) are found to be ubiquitously present.
For hERα, studies have revealed numerous possible mutations in both the exons and introns of
its gene ESR1 in both healthy and cancer patients, primary and metastatic tumors(Roodi, Bailey
et al. 1995, Segal and Dowsett 2014, Thomas and Gustafsson 2015). Because mutations found in
ER originated from a very limited population, and the incidence of mutations are far from
uncommon, the past EDCs evaluation studies focusing solely on “wildtype” ER can be incomplete
and biased. Consequently this raises a serious issue as to whether a susceptible subpopulation of
hER mutants exist that demonstrates altered susceptibility or responses to estrogenic and
xenoestrogenic chemicals in the environment. Therefore this study specifically investigated five
mutations of hERα inside or close to the ligand binding pocket for their effect to the interaction
between a broad spectrum of estrogenic EDCs and the protein receptors. The key questions that
were asked are: 1). Does a mutation occurring inside or outside the ligand binding pocket of hER
cause differential response to estrogenic EDCs? 2). If a mutation on hER causes change of
response to natural estrogen E2, will the direction and degree of deviation also apply to other
estrogenic EDCs? To address these two questions, we chose to use both computational modelling
and an experimental yeast bioluminescent estrogen assay to evaluate and then test the binding
and transactivation activity of wildtype and mutant hERα in the presence of EDCs from a wide
range of origins.
This chapter describes and reports the results from the computational modelling of the
interaction between selected estrogenic EDCs and wildtype/mutant hERα ligand binding domain.
As crystal structures for hERα ligand binding domain became available, the ligand-protein binding
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interaction was revealed for several compounds ranging from natural estrogens such as 17βestradiol to anti-estrogen pharmaceuticals such as 4OH-tamoxifen etc.(Andrew, Danielle et al.
1998, David, Yong et al. 1998). While crystal structures provided fundamental insights to the
interactions of ER and specific ligands, the rigid crystal structure is unable to provide
comprehensive representation of the dynamic and flexible nature of the protein receptor in vivo.
For ligand binding, critical conformations may be different from the crystal structure. In this study,
molecular dynamics simulation were employed to simulate the dynamics of hERα protein in vivo.
The aim of this study was to employ MD simulation to explore potential conformation changes
at the binding pocket when point mutation occurs and to evaluate how these mutations could
alter the binding affinity to estrogenic EDCs. It is hypothesized that computational modelling
through MD simulation and ensemble virtual docking can predict binding affinity changes caused
by mutations on the estrogen receptor, and the predicted binding changes could guide the
direction of in vitro bioassay validation. Two forms of hERα ligand binding domain, the agonist
form and antagonist form and their in silico mutated models were included in the MD simulation.
MD trajectories were clustered to select snapshots from each of the cluster, which were then
computationally docked with selected estrogenic ligands to evaluate the predicted binding
affinity.

3.2 Materials and Methods
Ligand preparation
The structure of 29 estrogenic compounds (Table 3.1) were obtained from the PubChem and
National Center for Toxicological Research Estrogen Receptor Binding Database (NCTRER)(Tong
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2008). Structures were prepared using the “Protonate 3D” module of MOE 2012 (Molecular
Operating Environment, Chemical Computing Group, Montreal, Canada) to add hydrogens with
pH condition of 7, and then energy-minimized to 0.05 kcal/mol/Å RMS (root mean square) energy
gradient using the MMFF94s force field(Halgren 1999) provided in MOE.
Protein structure preparation and in silico mutagenesis
Two x-ray crystal structures (PDB entry: 2B1Z, 3ERT) were selected for the docking and molecular
dynamics simulation study. 2B1Z represents the agonist binding form of hERα ligand binding
domain, while 3ERT represents the antagonist binding form of the ligand binding domain.
Structural preparation and in silico mutagenesis were conducted in MOE 2012. Firstly, the ligands
in 2B1Z and 3ERT structures were removed and one monomer of each protein structure was
retained. Then the protein structures were prepared by “homology modeling” module to fix
disconnected backbone, and then processed in the “structural preparation” module to add
missing atoms including hydrogen, and protonate according to pKa estimates of each residue at
pH 7. To select the sites for mutagenesis study, previous findings of hER mutations reported in
COSMIC cancer mutation database(Forbes, Bhamra et al. 2008) and literature were collected and
reviewed. Eventually five mutation sites inside and closed to the ligand binding pocket were
selected based on their position (Table 3.2, Fig 3.1). The mutations Asp351Tyr, Glu353Val,
Met396Val, Leu525Ala and Asp538Gly were performed in silico separately on 2B1Z and 3ERT,
generating a total of 10 structures. Structures were minimized with tether restraints of 0.5 to
RMS gradient of 0.1 kcal/mol/Å 2 using MMFF94x force field implemented in MOE.
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Table 3.1 Structure and relative binding affinity (experimental) of tested estrogenic compounds
ER_RBA

Activity Score

Activity
Category

Chemical
Class

diethylstilbestrol (DES)

3.98E+02

100

active
strong

Synthetic
estrogen

ethynyl estradiol

1.91E+02

96

active
strong

Synthetic
estrogen

4-hydroxy-tamoxifen

1.74E+02

95

active
strong

Anti-estrogen

17beta estradiol (E2)

1.00E+02

93

active
strong

Natural
estrogen

alpha zearalanol

3.02E+01

87

active
strong

Phytoestrogen

estriol

9.77E+00

81

active
strong

Natural
estrogen

estrone

7.24E+00

80

active
strong

Natural
estrogen

17alpha estradiol

3.09E+00

76

active
strong

Synthetic
estrogen

zearalanone

2.09E+00

74

active
strong

Phytoestrogen

tamoxifen

1.62E+00

73

active
strong

Anti-estrogen

coumestrol

8.91E-01

70

active
medium

Phytoestrogen

genistein

4.36E-01

66

active
medium

Phytoestrogen

Compound

Structure
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Table 3.1 Continued

ER_RBA

Activity Score

Activity
Category

Chemical
Class

norethynodrel

2.14E-01

63

active
medium

Synthetic
estrogen

HPTE

2.51E-01

63

active
medium

Pesticide
metabolite

4',6-dihydroxyflavone

1.51E-01

61

active
medium

Phytoestrogen

bisphenol B

8.51E-02

58

active
medium

Plasticizer

nonylphenol

2.95E-02

53

active
medium

Phenols Alkyl

4-t-octylphenol

1.50E-02

50

active
medium

Phenols Alkyl

bisphenol A (BPA)

7.80E-03

46

active
weak

Plasticizer

4'-hydroxychalcone

3.70E-03

43

active
weak

Phytoestrogen

4'-hydroxy flavanone

2.23E-03

40

active
weak

Phytoestrogen

5alpha dihydrotestosterone

1.30E-03

38

active
weak

Androgen

o,p'-DDT

1.41E-03

38

active
weak

Pesticide

chalcone

1.51E-03

38

active
weak

Phytoestrogen

ethyl 4-hydroxybenzoate

6.00E-04

34

active
weak

Phenols

Compound

Structure
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Table 3.1 Continued

ER_RBA

Activity Score

Activity
Category

Chemical
Class

Mestranol

2.24E+00

74

active
strong

Synthetic
estrogen

S-equol

1.51E-01

61

active
medium

Phytoestrogen

daidzein

2.20E-02

52

active
medium

Phytoestrogen

resveratrol

na

na

na

Phytoestrogen

Compound

Structure

na: no data available.
ER_RBA: estrogen receptor binding affinity (relative to 17β-estradiol) measured by rat uterine cytosol estrogen receptor
competitive receptor binding assay. Natural estrogen E2 has ER_RBA = 100. ER_RBA > 100 means ligand’s binding affinity is higher
than E2. ER_RBA=0 means no activity. All data was obtained from NCTRER (FDA National Center for toxicological Research
Estrogen Receptor Binding Database) (Blair, Fang et al. 2000, Fang, Tong et al. 2001, Branham, Dial et al. 2002, Tong 2008).
Activity Score: For compounds with log(ER_RBA) values over 1E-5 in NCTRER database, the ER_RBA activity was spanned onto
integer 20-100 activity range, making 100 the highest potency and 20 the lowest active potency.
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Table 3.2. Source of hERα mutagenesis sites and known biological effects
Mutagenesis
site

Source

Known Effect

Asp351Tyr

Breast cancer1

Increased estrogenicity triggered by antiestrogen
Tamoxifen

Glu353Val

Breast cancer2

Decreased affinity to estrogen found with Gln
mutation7

Met396Val

Breast cancer3

N/A

Leu525Ala

Artificial
mutation4

Decreased estrogen binding and transcriptional
activation

Asp538Gly

Breast Cancer5

Constitutively active receptor, Resistant to antiestrogen treatment6

1. (Catherino, Wolf et al. 1995) 2. (Karnik, Kulkarni et al. 1994) 3. (Roodi, Bailey et al. 1995) 4. (Kirk, Karen et al. 1996) 5. (Forbes,
Bhamra et al. 2008) 6. (Merenbakh-Lamin, Ben-Baruch et al. 2013) 7.(Ekena, Katzenellenbogen et al. 1998)
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Fig 3.1. hERα ligand binding domain and mutation sites. Mutation sites are marked in green with
residue tags in red. Helix-12 of the ligand binding domain is marked in brown. (A) agonist-bound
form (PDB entry: 2B1Z), helix-12 is in closed position. (B) antagonist-bound form (PDB entry:
3ERT), helix-12 is in open position. (C&D) Close view of mutation sites on 2B1Z. Glu353 and
Leu525 are inside the ligand binding pocket. Asp351 is on helix-3, outside the binding pocket,
facing helix-12. Asp538 is on the end of helix-12. Met 396 is on the end of helix-5, outside the
binding pocket.
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Molecular dynamics simulation
The prepared 2B1Z (agonist form), 3ERT (antagonist form) wildtype and mutant protein
structures without ligand were solvated in cube periodic box with 6 Å margin using the “Solvate”
module in MOE. Each model was then energy-minimized to RMS gradient of 0.1 kcal/mol/Å 2 using
CHARMM27 force field(Nicolas and Alexander 2000) in MOE with rigid water molecules
constraint. Molecular dynamics simulations were performed using NAMD v2.9 (James, Rosemary
et al. 2005) with CHARMM27 force field on Kraken supercomputer at National Institute for
Computer Science, Oak Ridge, TN and Newton HPC at University of Tennessee, Knoxville. Protein
models were heated from 0 to 300 K in 30 ps with heavy atom constraint of 0.5 Å, then
equilibrated in Isothermal–isobaric (NPT) ensemble at 300 K, 101 kPa for 500 ps. Production
simulation was performed at 300 K for 20 ns (50 ns for 2B1Z wildtype) in Canonical (NVT)
ensemble with time step of 2 fs, fixed length for bonds with hydrogen, rigid water constraint, and
Particle Mesh Ewald algorithm was applied to calculate electrostatic forces. Molecular dynamics
(MD) trajectories were saved every 0.5 ps, producing 40000 frames for each 20 ns simulation.
Trajectory clustering and selection of MD conformation
Molecular dynamics trajectories were firstly trimmed down to protein backbone only form, and
aligned using ProDy(Bakan, Meireles et al. 2011). Aligned trajectories were clustered based on
RMSD (root-mean-square atom-to-atom distance) using the Clustering Tool plugin (Luis Gracia,
Weill Cornell Medical College, New York, NY) featuring the quality-threshold clustering algorithm
implemented in VMD(Humphrey, Dalke et al. 1996). Clustering was performed with 9 clusters
specified, 1 Å cutoff threshold and step of 10 (use 1 of every 10 frames). N-terminal and Cterminal tail residues with large movement were excluded in clustering to minimize the unrelated
91

variance. One frame in each cluster was selected and based on the indices of the selected frames,
original full-size frame was extracted from the untrimmed MD trajectory as PDB files using ProDy.
Ensemble docking
The selected MD snapshots of hERα ligand binding domain (LBD) structures 2B1Z and 3ERT
wildtype and mutant, along with the starting structure for MD (referred as the crystal structures
herein) (a total of 10 conformations for each molecule model) were used to dock the 29
estrogenic ligands listed in Table 3.1. For crystal structures, water molecules were removed
except for one (water 8 in 2B1Z, water 2 in 3ERT) that is involved in the binding of various
hydroxylated ligands through a hydrogen bond network with Glu353 and Arg354(Humphrey,
Dalke et al. 1996, David, Yong et al. 1998, Shiau, Barstad et al. 1998). Similarly, a water molecule
close to Glu353 and Arg354 was reserved in docking for snapshots selected from MD trajectories.
Binding site for ligand docking was identified using the “Site Finder” module in MOE. For docking,
ligand bonds were allowed to rotate during placement. Initial placement of ligands was
conducted using Triangle Matcher method, with specified 1000 returned poses. The binding free
energy of poses from initial placement were estimated by London dG scoring function and the
top 30 poses were retained. The receptor atoms (within 6 Å distance from the ligands) and the
ligands of retained poses were refined through force field (MMFF94x) energy minimization to
0.01 kcal/mol/Å RMS energy gradient, with side chains of the receptor pocket set as free to move.
Final binding free energy scores were estimated by GBVI/WSA dG scoring function and the best
scored pose was used for final comparison.
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3.3 Results and Discussion
MD simulation of hERα LBD wildtype, mutants and ensemble docking results
MD simulation was performed for hERα ligand binding domain in the agonist-bound form (2B1Z)
and antagonist bound form (3ERT), including both the wildtype and mutant structures. RMSD
value for each simulation was calculated based on the protein backbone atoms and presented in
Fig 3.2. All MD simulations were performed for 20 ns except for 2B1Z-wildtype, 50 ns simulation
was conducted. The RMSD of 2B1Z structures were mostly within 2.5 Å, while 3ERT structures
exhibited larger RMSD, with most showing 3.5 to 4 Å. The higher RMSD for 3ERT MD simulation
is likely due to the different positioning of helix-12 in 3ERT that its helix-12 is in a more open
position with more flexibility and space to move.
The trajectories of MD simulation were clustered based on the RMSD of backbone atoms. One
snapshot was chosen from each of the 9 cluster to be used in the ensemble docking. Each of the
29 ligands listed in Table 3.1 was docked to 9 MD snapshots plus the starting structure, yielding
10 docking scores for each ligand/hER variant. The ensemble docking scores of hER wildtype and
mutant are presented as 1) the average of all 10 dockings, 2) the best (lowest value) among all
10 dockings, and 3) the docking score of the starting structure for MD (crystal structure)
(Supplemental Table 3.1).
Wildtype 2B1Z and 3ERT ensemble docking results and correlation with experimental binding
affinity and transcriptional activity
Wild type 2B1Z and 3ERT ensemble docking results including the “ensemble average”, “ensemble
best” and “crystal” structure docking scores are presented in Table 3.3 and Fig 3.2. To evaluate
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Fig 3.2. RMSD plots from MD simulation of 2B1Z and 3ERT wildtype and mutant structures.
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Fig 3.3. Column scatter plot for wildtype 2B1Z and 3ERT docking scores of 29 ligands. Bars
represent mean and standard deviation.
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the performance of ensemble docking in distinguishing ligands with different level of
estrogenicity, the relative binding affinity from competitive estrogen receptor binding assay
(ER_RBA), half-maximal effective concentration (EC50) from yeast bioluminescent estrogen
reporter assay were obtained from previous studies(Tong 2008, Sanseverino, Eldridge et al. 2009)
and listed in Table 3.3. Ligands in Table 3.3 are sorted by ER_RBA from the most potent to the
least potent. Out of the 29 ligands, all except resveratrol have ER_RBA available, while 13 of them
have EC50 estimated. The correlation between different docking scores, experimental relative
binding affinity and EC50 values are presented in Table 3.4.
PDB structure 2B1Z and 3ERT represent the agonist and antagonist binding forms respectively
for hERα LBD. The reason to include both conformations in the study was to examine which form
is more suited for virtual docking screening of estrogenic compounds. In our study, docking
scores obtained from 3ERT wildtype was larger than that of 2B1Z wildtype structures for any of
the docked ligand, whether the comparison was based on the ensemble average, ensemble best
or crystal docking scores (Table 3.3). When comparing the mean “crystal” docking scores of all
ligands, 3ERT averaged -10.8 kcal/mol, while 2B1Z averaged -13.0 kcal/mol, 2.2 kcal/mol smaller
than 3ERT. The mean of all ligands’ “ensemble average” and “ensemble best” scores for 2B1Z
and 3ERT also showed the similar difference of over 2 kcal/mol (Table 3.3 and Fig 3.3). Regarding
how well the docking scores correlate with the experimental ER_RBA, 3ERT wildtype showed
slightly less correlation than 2B1Z wildtype in “crystal” docking scores (-0.66 vs. -0.68), but
significantly weaker correlation in “ensemble average” scores than 2B1Z (-0.49 vs. -0.61, Table
3.4). The difference between the docking score of 2B1Z and 3ERT can be attributed to 3ERT’s
Helix-12, which is in the open position, leaving ligands with a larger space compared to 2B1Z,
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Table 3.3. Experimental relative binding affinity, EC50, ensemble docking average and best scores
and crystal structure docking scores for wildtype 2B1Z and 3ERT structures
ER_RBA

EC50
BLYES
(M)

2B1Z
ensemble
average

2B1Z
ensemble
best

2B1Z
crystal

3ERT
ensemble
average

3ERT
ensemble
best

3ERT
crystal

diethylstilbestrol (DES)

3.98E+02

5.30E-12

-10.0

-10.4

-9.6

-6.8

-8.5

-8.5

ethynyl estradiol (EE2)

1.91E+02

2.50E-11

-9.9

-10.8

-10.5

-6.8

-8.4

-8.4

4-hydroxy-tamoxifen

1.74E+02

1.86E-09

-12.7

-13.4

-13.0

-9.2

-10.8

-10.8

17beta estradiol (E2)

1.00E+02

6.30E-10

-9.4

-9.9

-9.6

-6.7

-8.0

-8.0

alpha zearalanol

3.02E+01

-

-10.7

-11.1

-10.6

-7.4

-8.5

-8.5

estriol

9.77E+00

-

-9.8

-10.5

-10.5

-6.9

-8.1

-8.1

estrone

7.24E+00

6.40E-09

-9.4

-9.9

-9.5

-6.5

-7.8

-7.8

17alpha estradiol

3.09E+00

1.10E-08

-9.5

-10.3

-9.5

-6.7

-7.8

-7.8

mestranol

2.24E+00

-

-10.7

-11.5

-10.8

-7.2

-8.5

-8.5

zearalanone

2.09E+00

1.90E-06

-10.6

-11.3

-10.6

-7.4

-8.4

-8.2

tamoxifen

1.62E+00

-

-12.5

-13.5

-12.8

-9.0

-10.3

-10.3

coumestrol

8.91E-01

3.30E-08

-8.3

-9.1

-8.4

-6.2

-6.9

-6.8

genistein

4.36E-01

3.86E-06

-9.0

-9.8

-8.9

-6.3

-7.1

-7.1

norethynodrel

2.14E-01

1.38E-04

-10.0

-10.5

-10.3

-7.1

-8.4

-8.4

HPTE

2.51E-01

-

-9.3

-9.8

-9.1

-7.0

-8.1

-8.1

equol

1.51E-01

-

-9.0

-9.5

-8.7

-6.5

-7.6

-7.6

4',6-dihydroxyflavone

1.51E-01

-

-8.7

-9.2

-8.5

-6.4

-7.4

-7.4

bisphenol B

8.51E-02

-

-9.1

-9.7

-8.7

-6.8

-7.6

-7.5

nonylphenol

2.95E-02

1.70E-05

-9.8

-10.4

-9.0

-7.0

-7.5

-7.5

daidzein

2.20E-02

-

-8.9

-9.5

-8.7

-6.4

-7.2

-7.2

4-t-octylphenol

1.50E-02

-

-8.6

-9.0

-8.1

-6.5

-7.1

-6.9

bisphenol A (BPA)

7.80E-03

-

-8.7

-9.1

-8.5

-6.5

-7.4

-7.1

4'-hydroxychalcone

3.70E-03

-

-8.6

-9.2

-8.0

-6.3

-7.0

-7.0

4'-hydroxy flavanone

2.23E-03

-

-8.6

-9.2

-8.2

-6.4

-6.8

-6.8

5alpha
dihydrotestosterone

1.30E-03

3.71E-06

-9.6

-10.2

-9.7

-6.7

-8.0

-8.0

o,p'-DDT

1.41E-03

-

-9.2

-9.6

-9.0

-7.1

-8.0

-7.4
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Table 3.3 Continued

ER_RBA

EC50
BLYES
(M)

2B1Z
ensemble
average

2B1Z
ensemble
best

2B1Z
crystal

3ERT
ensemble
average

3ERT
ensemble
best

3ERT
crystal

chalcone

1.51E-03

-

-8.6

-9.2

-7.5

-6.2

-6.9

-6.9

ethyl 4hydroxybenzoate

6.00E-04

1.40E-06

-7.0

-7.7

-6.5

-5.3

-5.9

-5.5

resveratrol

-

-

-8.5

-9.4

-7.9

-6.4

-7.0

-6.8

min

6.00E-04

5.30E-12

-12.7

-13.5

-13.0

-9.2

-10.8

-10.8

max

3.98E+02

1.38E-04

-7.0

-7.7

-6.5

-5.3

-5.9

-5.5

mean

3.29E+01

1.28E-05

-9.5

-10.1

-9.3

-6.8

-7.8

-7.8

stdev

8.57E+01

3.64E-05

1.2

1.2

1.4

0.8

1.0

1.0

-: no data available.
EC50_BLYES: half-maximal effective concentration (mol/L) previously determined by bioluminescent yeast estrogen
reporter(Sanseverino, Eldridge et al. 2009).
2B1Z and 3ERT are the two crystal structure of hERα ligand binding domain representing the agonist-bound and
antagonist bound conformation respectively. Ensemble average is the averaged docking score (predicted binding
affinity from GBVI/WSA dG scoring function, kcal/mol) from all ensemble docking. Ensemble best is the lowest
docking score from all ensemble docking. Crystal is the docking score using the crystal structure of the receptor
protein.
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Table 3.4. Pearson’s correlation between experimental binding affinity and EC50, ensemble
docking average and best scores and crystal structure docking scores
logER_RBA

logEC50
(BLYES)

2B1Z
ensemble
average

2B1Z
ensemble
best

2B1Z
crystal

3ERT
ensemble
average

3ERT
ensemble
best

logER_RBA

1.00

logEC50 (BLYES)

-0.81*

1.00

2B1Z ensemble
average

-0.61*

0.21

1.00

2B1Z ensemble best

-0.61*

0.21

0.99*

1.00

2B1Z crystal

-0.68*

0.26

0.97*

0.97*

1.00

3ERT ensemble
average

-0.49*

0.15

0.96*

0.95*

0.92*

1.00

3ERT ensemble best

-0.63*

0.34

0.97*

0.95*

0.96*

0.96*

1.00

3ERT crystal

-0.66*

0.35

0.97*

0.96*

0.96*

0.94*

0.99*

3ERT
crystal

1.00

*: p<0.05
logER_RBA: log trasnformed estrogen receptor relative binding affinity measured by rat uterine cytosol estrogen
receptor competitive receptor binding assay, obtained from NCTRER (FDA National Center for toxicological Research
Estrogen Receptor Binding Database) (Blair, Fang et al. 2000, Fang, Tong et al. 2001, Branham, Dial et al. 2002, Tong
2008).
logEC50 (BLYES): log transformed half-maximal effective concentration previously determined by bioluminescent
yeast estrogen reporter(Sanseverino, Eldridge et al. 2009).
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hence yield lower predicted binding affinity. The majority of the 29 ligands except tamoxifen and
4-hydroxy-tamoxifen are agonists of hER, and 3ERT yielded weaker predicted binding affinity and
slightly poorer correlation with experimental ER_RBA as compared to 2B1Z. Consequently,
further downstream data analysis was primarily focused on 2B1Z derived results. The data for
relative comparison to 3ERT is available for further use (see Supplemental Table 3.1).
ER_RBA is the experimental binding affinity obtained through competitive ligand binding assay
in the presence of natural estrogen E2. Out of the 29 tested ligands, 28 of them have ER_RBA
data available. These ligands ranged from strong to medium ER binder according to the ER_RBA
based annotation in NCTRER database, and their ER_RBA spread from 6E-4 to 3.98E+2, a range
of approximately six magnitude (Table 3.1). According to ER_RBA, the strongest ER binder is DES
while the weakest binder is ethyl 4-hydroxybenzoate. In our docking results of 2B1Z wildtype,
ethyl 4-hydroxybenzoate was indeed predicted to be the weakest binder, based on either
“ensemble average”, “ensemble best” or “crystal” scores. Yet the predicted strongest binder was
not DES, but tamoxifen. To further assess the performance of the docking scheme, correlations
between virtual docking scores and experimental binding and yeast bioassay results were
analyzed (Table 3.4). logER_RBA had moderate correlation with either 2B1Z “ensemble average”,
“ensemble best” or “crystal”. “Ensemble best” and “ensemble average” yielded the same
coefficient of -0.61, while “crystal” yielded slightly higher coefficient than “ensemble average”
and “ensemble best” (-0.68 vs. -0.61). These results suggest that for wildtype 2B1Z docking,
crystal structure actually provided slightly better performance in distinguishing the binding
affinity of the tested 29 ligands. Experimental ligand potency data evaluated by yeast estrogen
bioluminescent reporter BLYES(Sanseverino, Eldridge et al. 2009) in the form of EC50 were also
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available for 13 of the 29 ligands. The cited EC50 data represent the potency of ligands in
activating hER and triggering the reporter bioluminescent genes, while ER_RBA focused on the
ligand binding process without considering the subsequent gene transactivation. Despite the
difference, the two experimental data, EC50 of the 13 ligands, agrees well with their ER_RBA, in
a strong correlation of -0.81 (Table 3.4). However there were no statistically significant
correlations found between EC50 and 2B1Z wildtype docking scores. Collectively, the results from
correlation analysis suggest that the ability of the docking scheme with 2B1Z to distinguish
between strong to medium hER binders is moderate at best. Although the ligand binding domain
of hERα demonstrated very good selectivity in previous virtual screening studies, these success
results were evaluated on its ability to distinguish between agonist and decoys with over 1000
ligands been screened(Schapira, Abagyan et al. 2003, Harris, Eldridge et al. 2014). In comparison,
our study only docked a small number of 29 known hERα binders without inclusion of decoys.
The fact that all docked ligands have medium to strong hERα binding potency and the small scale
of screening could be the reason for the only moderate correlation between our docking scores
and the experimental binding affinity.
In order to make comparison between mutant and wildtype docking, one of the three different
types of docking scores needs to be determined. For several considerations as discussed below,
“ensemble average” was eventually selected over “ensemble best” and “crystal” scores. Firstly,
“crystal” scores was excluded since for the mutant hER receptors, there was no real “crystal”
structure. As the purpose of MD simulation of the mutant hER receptor was to explore potential
structural changes as the result of mutations, using the “crystal” score would defeat this purpose.
Additionally, to support the use of “ensemble average”, Glu353Val mutant docking scores were
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Fig. 3.4. Comparison of docking scores for 2B1Z wildtype and Glu353Val mutant. (A) Ensemble
average docking scores, (B) Ensemble best docking scores, (C) Crystal docking scores.
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Table 3.5. 2B1Z wildtype and Glu353Val mutant docking scores comparison
ensemble average

ensemble best

crystal

2B1Z_wildtype

2B1Z_353

2B1Z_wildtype

2B1Z_353

2B1Z_wildtype

2B1Z_353

diethylstilbestrol (DES)

-10.0

-8.9

-10.4

ethynyl estradiol

-9.9

-9.3

-10.8

-10.4

-9.6

-7.5

-10.5

-10.5

-8.2

4-hydroxy-tamoxifen

-12.7

-11.7

-13.4

-13.4

-13.0

-10.9

17beta estradiol (E2)

-9.4

-8.5

-9.9

alpha zearalanol

-10.7

-9.7

-11.1

-9.6

-9.6

-7.2

-11.1

-10.6

-8.4

estriol

-9.8

-8.7

-10.5

-9.7

-10.5

-7.8

estrone

-9.4

-8.4

-9.9

-9.6

-9.5

-7.3

17alpha estradiol

-9.5

-8.5

-10.3

-9.5

-9.5

-7.4

zearalanone

-10.6

-9.5

-11.3

-10.9

-10.6

-8.2

tamoxifen

-12.5

-11.6

-13.5

-13.2

-12.8

-10.3

coumestrol

-8.3

-7.6

-9.1

-8.9

-8.4

-6.4

genistein

-9.0

-8.1

-9.8

-9.4

-8.9

-7.0

norethynodrel

-10.0

-9.1

-10.5

-10.1

-10.3

-8.1

HPTE

-9.3

-8.3

-9.8

-9.5

-9.1

-7.3

4',6-dihydroxyflavone

-8.7

-7.9

-9.2

-9.7

-8.5

-7.0

bisphenol B

-9.1

-8.3

-9.7

-10.1

-8.7

-7.3

nonylphenol

-9.8

-8.5

-10.4

-9.9

-9.0

-7.3

4-t-octylphenol

-8.6

-7.6

-9.0

-9.3

-8.1

-6.4

bisphenol A

-8.7

-7.7

-9.1

-9.0

-8.5

-6.4

4'-hydroxychalcone

-8.6

-8.0

-9.2

-8.9

-8.0

-6.9

4'-hydroxy flavanone

-8.6

-7.7

-9.2

-9.5

-8.2

-6.3

5alpha dihydrotestosterone

-9.6

-8.8

-10.2

-9.9

-9.7

-7.8

o,p'-DDT

-9.2

-8.3

-9.6

-9.6

-9.0

-7.6

chalcone

-8.6

-7.6

-9.2

-8.7

-7.5

-6.8

ethyl 4-hydroxybenzoate

-7.0

-6.4

-7.7

-9.6

-6.5

-5.7

mestranol

-10.7

-9.4

-11.5

-10.7

-10.8

-9.0

equol

-9.0

-8.0

-9.5

-9.6

-8.7

-6.8

daidzein

-8.9

-7.9

-9.5

-8.9

-8.7

-6.9

resveratrol

-8.5

-7.9

-9.4

-9.0

-7.9

-6.8

min

-12.7

-11.7

-13.5

-13.4

-13.0

-10.9

max

-7.0

-6.4

-7.7

-8.7

-6.5

-5.7

mean

-9.5

-8.6

-10.1

-9.9

-9.3

-7.5

stdev

1.2

1.1

1.2

1.1

1.4

1.1
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used to demonstrate the suitability of “ensemble average” score in distinguishing the mutation
effect (Table 3.5, Fig 3.4). When comparing the “ensemble average” and “ensemble best” scores
of 2B1Z wildtype and 2B1Z_353 mutant, “ensemble average” better reflected the expected
weaker binding as a result of Glu353Val mutation. Glu353Val mutant included in this study can
be viewed as a positive control for predicted weaker binding, as Glu353 residue is the essential
residue in hER ligand binding pocket. Through its charged side chain, Glu353 supports the
anchoring and correct positioning of many ligands including the natural estrogen E2 and ligands
with similarly positioned hydroxyl group. When Glu353 was mutated into Val, all ligands rely on
the electrostatic interaction with Glu353 would suffer from significantly weaker binding. From
Fig.3.4, it’s clear that “ensemble average” was able to differentiate 2B1Z wildtype and Glu353Val
mutant while “ensemble best” failed to distinguish. Therefore “ensemble average” was
eventually chosen as the score for wildtype and mutant binding affinity comparison.
Comparison of 2B1Z mutant and wildtype docking results, effect of mutation on ligand docking
scores
The “ensemble average” docking scores for the five hER mutants was compared with the 2B1Z
wildtype and presented as percentage of changes (Table 3.6). A negative percentage means
smaller predicted binding affinity compared to the wildtype. Docking scores are also plotted as
column scatter plot, as presented in Fig 3.5.
When examining the docking scores of all 29 ligands as a whole, all five mutants demonstrated
various degrees of reduction in predicted binding affinity compared to the wildtype (Fig3.5). For
docking scores, the larger negative value has the higher predicted binding affinity. Among the
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Fig 3.5. Column scatter plot of ensemble average docking scores of 2B1Z wildtype and mutants
for all 29 ligands. Bars represent mean and standard deviation.
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Table 3.6. Percentage changes of ensemble average docking scores of 2B1Z mutants in
comparison to the wildtype
2B1Z_351 2B1Z_353 2B1Z_396 2B1Z_525 2B1Z_538
diethylstilbestrol (DES)
ethynyl estradiol
4-hydroxy-tamoxifen
17beta estradiol (E2)
alpha zearalanol
estriol
estrone
17alpha estradiol
zearalanone
tamoxifen
coumestrol
genistein
norethynodrel
HPTE
4',6-dihydroxyflavone
bisphenol B
nonylphenol
4-t-octylphenol
bisphenol A
4'-hydroxychalcone
4'-hydroxy flavanone
5alpha dihydrotestosterone
o,p'-DDT
chalcone
ethyl 4-hydroxybenzoate
mestranol
equol
daidzein
resveratrol
Max
Min
Mean
Stdev

-7%
-4%
-5%
-5%
-5%
-5%
-4%
-6%
-6%
-5%
-3%
-7%
-6%
-5%
-6%
-7%
-5%
-5%
-6%
-4%
-6%
-4%
-4%
-6%
-5%
-7%
-8%
-7%
-5%
-8%
-3%
-5%
1%

-11%
-6%
-8%
-10%
-9%
-11%
-11%
-10%
-10%
-7%
-8%
-10%
-9%
-11%
-9%
-9%
-13%
-12%
-11%
-8%
-11%
-9%
-10%
-12%
-8%
-12%
-10%
-11%
-7%
-13%
-6%
-10%
2%
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-5%
-7%
-6%
-6%
-4%
-5%
-7%
-4%
-5%
-6%
-3%
-9%
-8%
-4%
-9%
-6%
-6%
-6%
-6%
-8%
-7%
-10%
-5%
-5%
-6%
-11%
-9%
-9%
-7%
-11%
-3%
-7%
2%

-3%
-1%
0%
-3%
-1%
-3%
-4%
-4%
-2%
-1%
1%
-5%
-2%
-2%
-3%
-1%
-1%
-3%
-2%
0%
-4%
-2%
0%
-2%
-1%
-6%
-4%
-6%
-5%
-6%
1%
-2%
1%

-7%
-5%
-5%
-5%
-7%
-8%
-8%
-6%
-6%
-8%
-5%
-8%
-7%
-6%
-5%
-5%
-8%
-6%
-6%
-4%
-6%
-5%
-3%
-9%
-3%
-9%
-6%
-10%
-7%
-10%
-3%
-6%
2%

five mutants, 2B1Z_353 mutant yielded the largest decrease in predicted binding affinity; on
average, docking scores of 2B1Z_353 for all 29 ligands were 10% higher than the wildtype (Table
3.6). On the other hand, 2B1Z_525 mutant produced the smallest decrease in docking scores; the
average percentage of change for all 29 ligands was only -2%. The other three mutants, 2B1Z_351,
2B1Z_396 and 2B1Z_538 all demonstrated modest reduction of predicted binding, with the
average percentage of change being -5%, -7% and -6% respectively. The difference in docking
scores between the wildtype and mutants for individual ligand varied as well. 2B1Z_353 yielded
the steepest decreases, with percentage of change ranged from -13% to -6%. For 2B1Z_351,
2B1Z_396, 2B1Z_538, percentage of decrease ranged from -8% to -3%, -11% to -3% and -10% to
-3%, respectively. 2B1Z_525, however, was the only mutant that showed no change or an
increase of binding affinity for several ligands; its percentage of change ranged from -6% to 1%.
Overall, ensemble docking simulation predicted decrease of binding affinity for nearly all 29
ligands when the tested five hERα mutations occur. In the five hER mutations, Glu353Val was
predicted to yield the highest reduction of binding affinity, while Leu525Ala was predicted to
yield the least reduction, with some ligands showed no change or slight increase.
To interpret the predicted results, it is necessary to understand the position, and potential role
of each individual mutated residue of the receptor. Among the five mutation sites, only Glu353
and Leu525 are considered inside the binding pocket that can directly interact with ligands, while
Asp351 and Met396 and Asp538 are in the vicinity of the binding pocket (Fig 3.1). Glu353Val and
Leu525Ala mutations can be better evaluated through virtual docking as the mutations create
more drastic changes directly inside the binding cavity that are easier to be reflected on the
docking scores. Glu353 residue features negatively charged side chain that is responsible for
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critical electrostatic interaction with ligands with hydroxyl group. Mutating Glu353 to Val
eliminates this critical ligand-receptor electrostatic interaction. Such drastic change was clearly
reflected on the noticeable shift of 2B1Z_353 docking scores. Leu525 is located at the opening
end of the binding pocket, and helps shape the binding cavity through its hydrophobic side chain.
Mutating Leu525 to Ala displaces the long hydrophobic side chain, creating opener binding cavity.
Depending on the structure of a ligand, a more open binding cavity could either benefit or
negatively affect the binding affinity. The docking of 29 ligands to Leu525Ala seems to support
this perception, as the prediction posted mostly small decreases of binding affinity, while several
remained the same or had slightly increase. Although Asp351 residue is close to Glu353, its side
chain stretches outwards of the ligand binding pocket (Fig 3.1). Previous studies have reported
that Asp351 residue interacts with antagonists such as tamoxifen (Levenson, Catherino et al.
1997, Levenson and Jordan 1998). However, whether the Asp351Tyr mutation can cause a
structural change in the binding pocket that affects the binding of other agonists was unknown.
In our study, the ensemble docking of 2B1Z_351, 2B1Z_396 and 2B1Z_538 predicted decreases
of binding affinity as the result of these mutations for all 29 ligands. Since Asp351, Met396,
Glu538 are outside the binding pocket, the predicted changes of binding affinity through
ensemble docking of MD sampled conformations indicate the occurrence of structural transition
during MD simulation that made the binding pocket of the receptor less fit to the ligands.
Nevertheless, as the difference between 2B1Z wildtype and mutant docking scores was very
modest, the accuracy of the predictions warrants validation through experimental mutagenesis
study.
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3.4 Conclusion
In this study, ensemble docking of selected MD conformations of wildtype hERα ligand binding
domain showed moderate correlation with previous experimental binding assay data, suggesting
a relatively good performance of the docking scheme, especially considering the evaluated
ligands were strong to medium ER binders. When comparing the 2B1Z derived docking results
between hERα wildtype and the five mutants, ensemble docking simulation predicted decrease
of binding affinity for nearly all 29 ligands when the tested five hERα mutations occur. Among
the five hER mutations, Glu353Val was predicted to yield the highest reduction of binding affinity,
while Leu525Ala was predicted to yield the least reduction, with some ligands demonstrated no
change or slightly increase in binding affinity. However, as the difference between 2B1Z wildtype
and mutant docking scores was very modest, the accuracy of the predictions requires further
validation through experimental mutagenesis study.
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Chapter 4. Evaluating the Effects of Human Estrogen Receptor
Mutations in Response to environmental EDCs using Yeast
Bioluminescent Estrogen Reporter

112

Abstract
In this chapter, the yeast estrogen bioreporters were constructed to test the biological role of
human estrogen receptor alpha (hERα) mutation in altering ligand binding and transcriptional
response to environmental chemicals with a wide variety of structure and origin. In order to
provide a comparable platform, five mutated hERα genes, each containing a missense mutation
close to the ligand binding pocket, along with the wild type, were integrated separately into the
same location of yeast genome as single copy gene, and expressed by the same promoter and
terminator. Each hER mutant carrying yeast strain was also transformed with a bioluminescent
reporter plasmid which contains the estrogen response element controlled promoter, allowing
the evaluation of transcriptional activity triggered by ligand-receptor interaction. A total of 12
EDCs including the natural estrogen 17β-estradiol (E2), synthetic hormone, plasticizer,
phytoestrogen and industrial compound were evaluated with the wildtype and mutant hER yeast
bioreporters.

4.1 Introduction
hERα is a nuclear receptor that can regulate gene expression when activated through ligand
binding and subsequent conformational change. hERα plays critical roles in the regulation of
hormonal responses and is highly related to critical diseases including breast cancer, osteoporosis
etc. The ligand-dependent transcriptional activation of hER requires other essential coregulators
and heterologous expression of the human estrogen receptor with fully functional transcriptional
activity relies on the presence of proper coregulators in the selected hosts. Human estrogen
receptor alpha were find fully functional as transcriptional activator in S. cerevisiae, but not in
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prokaryotic organisms such as E.coli(Metzger, White et al. 1988). As the most basic eukaryotic
organism, Saccharomyces cerevisiae is a well characterized host with efficient molecular
manipulation tools available, and has been widely used for mammalian gene expression. The fact
that human estrogen receptor can maintain full transcriptional activity in S. cerevisiae lead to
many uses of it for hER structural and functional studies. Particularly, manipulating and
maintaining yeast cell is much easier, quicker and lower cost compared to working with
mammalian cells.
The aim of this present study was to take advantage of the yeast estrogen bioreporter system as
a platform to test the biological role of human estrogen receptor alpha (hERα) mutation in
altering ligand binding and transcriptional response to environmental chemicals with a wide
variety of structure and origin. In order to provide a comparable platform, five mutated hERα
genes, each containing a missense mutation close to the ligand binding pocket, along with the
wild type, were integrated separately into the same location of yeast genome as single copy gene,
and expressed by the same promoter and terminator. Each hER mutant carrying yeast strain was
also transformed with a bioluminescent reporter plasmid which contains the estrogen response
element controlled promoter, allowing the evaluation of transcriptional activity triggered by
ligand-receptor interaction. These constructed yeast reporters provided the opportunity to
quickly evaluate the transcriptional activity changes when certain mutations occurred on hERα.
A total of 12 EDCs including the natural estrogen 17β-estradiol (E2), synthetic hormone,
plasticizer, phytoestrogen and industrial compound were evaluated with the wildtype and
mutant hER yeast bioreporters.
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4.2 Constructing New BLYES and Variant Reporters Carrying hER Mutations and
Optimizing the Chemical Testing Protocol
4.2.1 Methods and Materials
Chemicals, strains, medium and reagents
All EDCs used in the study are listed in Table 4.1. All chemicals were obtained from Sigma-Aldrich
(St. Louis, MO). Saccharomyces cerevisiae BY4742 (MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0) was
purchased from the American Type Culture Collection (ATCC 201389™). YPD medium (yeast
extract 10 g/L, peptone 20g/L, glucose 20 g/L, 18 g/L of agar for plate) was used for growth and
maintain of untransformed yeast strain. For selection of transformant carrying KanMX4 selective
marker, 300 mg/L effective concentration of antibiotic G418 was added to the YPD medium.
Yeast synthetic drop medium without uracil (YSD -ura) was used for selecting and maintaining
yeast strains harboring plasmid with ura3 selective marker. YSD medium was made according to
the manufacturer’s instruction, and contains: 1) 1.92 g/L yeast synthetic drop-out media
supplements (Sigma-Aldrich, St. Louis, MO, cat# Y1501), 2) 6.7 g/L yeast nitrogen base without
amino acids (Sigma-Aldrich, St. Louis, MO, cat# Y0626), 3) 20g/L dextrose. Because ammonium
sulfate contained in yeast nitrogen base can disrupt the function of G418, the minimal medium
for KanMX4 and ura3 selection was made with: 1) 1.92 g/L yeast synthetic drop-out media
supplements (Sigma-Aldrich, St. Louis, MO, cat# Y1501), 2) 1.7 g/L yeast nitrogen base without
amino acids and ammonium sulfate (Sigma-Aldrich, St. Louis, MO, cat# Y1251), 3) 20g/L dextrose,
4) 300 mg/L effective concentration of G418. This medium is only suitable for maintaining strains,
not suitable for initial yeast transformant selection due to very low yield of colonies.
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Table 4.1 Estrogenic compounds structures and relative binding affinity
CAS
Registry
Number

ER_RBA

Activity
Category

Category

diethylstilbestrol
(DES)

56-53-1

398.10001

active strong

Pharmaceutical,
synthetic
hormone

ethynyl estradiol

57-63-6

190.5

active strong

Pharmaceutical,
synthetic
hormone

17β estradiol
(E2)

50-28-2

100

active strong

Natural
hormone

mestranol

72-33-3

2.24

active strong

Pharmaceutical,
synthetic
hormone

tamoxifen
citrate

5496524-1

1.62

active strong

Pharmaceutical,
anti-estrogen

coumestrol

479-13-0

0.89099997

active medium

Phytoestrogen

genistein

446-72-0

0.43599999

active medium

Phytoestrogen

S-equol

531-95-3

0.15099999

active medium

Phytoestrogen

4-nonylphenol

2515452-3

0.0295

active medium

Industrial
compound

daidzein

486-66-8

0.022

active medium

Phytoestrogen

bisphenol A

80-05-7

0.0077999998

active weak

Plasticizer

Resveratrol

501-36-0

na

na

Phytoestrogen

Structure

ER_RBA, activity score and activity category are obtained from NCTRER database (FDA National Center for toxicological Research Estrogen
Receptor Binding Database)(Tong 2008).
ER_RBA: estrogen receptor binding affinity (relative to 17β-estradiol) measured by rat uterine cytosol estrogen receptor competitive receptor
binding assay. Natural estrogen E2 has ER_RBA = 100. ER_RBA > 100 means ligand’s binding affinity is higher than E2. ER_RBA=0 means no activity.
All data was obtained from NCTRER (FDA National Center for toxicological Research Estrogen Receptor Binding Database) (Blair, Fang et al. 2000,
Fang, Tong et al. 2001, Branham, Dial et al. 2002, Tong 2008).
Activity Score: For compounds with log(ER_RBA) values over 1E-5 in NCTRER database, the ER_RBA activity was spanned onto integer 20-100
activity range, making 100 the highest potency and 20 the lowest active potency.
na: no data available.
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Chemically competent Escherichia coli TOP10 (Invitrogen, Carlsbad, CA) was used as the host for
transforming constructed plasmids following the manufacturer’s protocol. Growth and
maintenance of E. coli TOP10 was on Luria-Bertani medium at 37°C and 100 µg/ml of ampicillin
was added when ampicillin-resistant plasmid selection was needed. Plasmid isolation was
performed using Zippy Plasmid Miniprep Kit (Zymo Research, Irvine, CA). T4 ligase and all
restriction endonucleases were purchased from Promega (Madison, WI). All PCR reactions were
carried out with Q5 High-Fidelity DNA Polymerase (New England Biolabs, MA). All
oligonucleotides used in this section are listed in Table 4.2.
Plasmids
pHO-Poly-KanMX4-HO was a gift from David Stillman (Addgene plasmid # 51662)(Voth, Richards
et al. 2001). p424GPD was provided by Melinda Hauser (University of Tennessee,
Knoxville)(Dominik, Rolf et al. 1995). The base plasmid pEREMEL1-Lux was a gift from Tingting Xu
(Center for Environmental Biotechnology, University of Tennessee). pEREMEL1-Lux is a selfreplicative plasmid featuring an estrogen response element (ERE) fused MEL1 promoter, which
initiates transcription when bounded by activated estrogen receptor protein. Viral 2A elements
were used to link and co-express six essential genes (frp and luxCDABE) for bioluminescence
production under the control of ERE fused MEL1 promoter (Fig 4.1)(Xu, Ripp et al. 2014).
Cloning hERα gene from Saccharomyces cerevisiae BLYES strain
S. cerevisiae BLYES strain carries a genomic integrated human estrogen receptor alpha
gene(Sanseverino, Gupta et al. 2005). However, from previous literature there was no
information regarding the actual sequence of this integrated gene. For comparison purpose, the
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Table 4.2 Primers and oligonucleotides used in bioreporter constructions.
Primer Name

Sequence (5'->3')

Template

Description

HO_F

ttaattatcctgggcacgag

HO_R

ACTGTAAGATTCCGCCACAT

pHO-424GPDhER

Amplify the DNA fragment for single-copy genomic
integratgration of hER expression cassette

HOPoly_cyc1t_GPD_F

gtacgctgcaggtcgacggatccccGGTAC
CGGCCGCAAATTA
p424GPD

Amplify the promoter-terminator (GPD-CYC1) region
of p424GPD

hER-wt

Amplify hER-wt gene, allow insertion of the amplified
gene to the p424GPD or pHO-GPDp-CYC1t-KanMX4HO plasmid's polylinker site.

hER-y

Amplify hER-y gene, allow insertion to p424GPD or
pHO-GPDp-CYC1t-KanMX4-HO plasmid’s polylinker
site.

hER-y

Amplify hER-y from S. cerevisiae BLYES strain, contain
restriction site, and allow ligation to p424GPD.

p424GPD or
pHO-GPDpCYC1t-KanMX4HO

Amplify and linearize the p424GPD plasmid ending
with BamHI and EcoRI sites.

pEREMEL1-lux

Amplify/linearize the pERMEL1-lux plasmid without
the EREMEL1 fragment.

ERECYC1

Amplify ERECYC1 sequence

pEREMEL1-lux

Amplify pEREMEL1-Lux without the 2micron
fragment

S. cerevisiae
genomic DNA

Amplify S20 fragment from yeast genome

pS20-EREMEL1lux

Amplify and linearize p20-pEREMEL1-Lux plasmid for
yeast genomic integration.

HOPoly_cyc1t_GPD_R

agatctggcgcgccttaattaacccTCGAG
TTTATCATTATCAATACTGCC

shER_gib_HO_F

cgacggatctagaactagtgATGACTATG
ACATTACACAC

shER_gib_HO_R

tatcgataagcttgatatcgTTATTAGACT
GTTGCTGGG

ohER_gib_HO_F

cgacggatctagaactagtgATGACCATG
ACCCTCCACAC

ohER_gib_HO_R

tatcgataagcttgatatcgTTATTAACCG
TGGCAGGGAA

ohER_F_BamHI

gatgcaGGATCCATGACCATGACCCT
CCACACCAA

ohER_R_EcoRI

cgatgcGAATTCACCGTGGCAGGGA
AACCCTCT

P424_BamHI_F

CACTAGTTCTAGATCCGTC

P424_EcoRI_R

CGATATCAAGCTTATCGATA

pERE_Up_pro

aagcttggcgtaatcatggt

pERE_Down_pro

ggtaccATGGGCACCAAGA

ERECYC1_F+pERE

ctatgaccatgattacgccaagcttgagctCA
AAGTCAGGTCA

ERECYC1_R+pERE

TGATCTTCTTGGTGCCCATggtaccA
TTAGTGTGTGTATTTGTGTTTGC

S20_pERE_F

gtctgTTTGGTAGCGGCTGCTTTATat
ccgatgataagctgtcaa

S20_pERE_R

attatATGATATAAAGGCGCCTGGCt
gaagcacagatgcttcgtt

20-up_F

GCCAGGCGCCTTTATATCAT

20_down_R

ATAAAGCAGCCGCTACCAAA

20-up_R

TTTGCGAAACCCTATGCTCT

20-down_F

AATGGAAGGTCGGGATGAG

S. cerevisiae BLYES: yeast bioluminescent estrogen reporter previous developed(Sanseverino, Gupta et al. 2005).
hER-wt: wildtype 595 amino acids human estrogen alpha
hER-y: human estrogen receptor alpha in S. cerevisiae BLYES strain(Sanseverino, Gupta et al. 2005).
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Fig 4.1. Schematic of plasmid pERMEL1-lux, pERECYC1-lux and pS20-EREMEL1-Lux. pERECYC1-lux
was constructed by replacing the promoter of pEREMEL1-lux with ERECYC1 promoter. pS20EREMEL1-lux was constructed by replaced the 2µ origin sequence with the S20 homologous
sequence, a DNA fragment amplified from the yeast genome.
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hERα gene in the BLYES strain was cloned and designated as hER-y. To clone the hER-y gene, the
genomic DNA of S. cerevisiae BLYES strain was extracted (YeaStar Genomic DNA Kit, Zymo
Research, Irvine, CA) and PCR amplified by Q5 high-fidelity polymerase with ohER_F_BamHI and
ohER_R_EcoRI primers. PCR product was gel purified and ligated to p424GPD within BamHI and
EcoRI sites. The resulted plasmid was named as p424GPD-hER-y. Cloned hER-y gene was
sequenced by ABI 3730 DNA Analyzer at the Molecular Biology Sequencing Facility at University
of Tennessee (Thermo Fisher Scientific, Waltham, MA).
Synthesizing wild type hERα gene
Human estrogen receptor alpha was found present in several isoforms, as listed in the database
of National Center for Biotechnology Information (NCBI). The 595 amino acids hERα isoform 1
was commonly considered as the full-length wild type form and was chosen for this study and
named as hER-wt. The corresponding gene was condon-optimized for yeast expression and
synthesized by GenScript (Piscataway, NJ). The synthesized hER-wt gene sequence is presented
in Table 4.3.
Construction of hER genome integration plasmids (pHO-GPDp-hER-CYC1t-KanMX4-HO)
HO-Poly-KanMX4-HO plasmid was linearized by SmaI digestion and gel purified (Wizard SV Gel
and PCR Clean-Up System, Promega, Madison, WI). The GPDPromoter-polylinker-CYC1Terminator
fragment of p424GPD was PCR amplified with HOPoly_cyc1t_GPD_F and HOPoly_cyc1t_GPD_R
primers, which contain sequences overlapping the regions flanking the SmaI site of HO-PolyKanMX4-HO. PCR product was then gel purified and ligated into the linearized HO-Poly-KanMX4HO plasmid using Gibson Assembly (New England BioLabs, Ipswich, MA)(Gibson, Young et al.
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Table 4.3. Synthesized DNA sequences for bioreporter constructions
Synthesized DNA sequence

Wildtype hERα

ATGACTATGACATTACACACCAAGGCATCCGGTATGGCATTGTTGCACCAAATCCAA
GGTAACGAATTAGAACCATTAAATAGACCACAATTGAAAATTCCTTTAGAAAGACC
ATTGGGTGAAGTTTATTTGGATTCTTCAAAGCCTGCAGTCTATAATTACCCAGAAGG
TGCTGCATACGAGTTTAATGCCGCTGCAGCCGCTAACGCTCAAGTCTATGGTCAAAC
CGGTTTGCCTTACGGTCCAGGTTCTGAAGCAGCCGCTTTTGGTTCAAATGGTTTAGG
TGGTTTCCCACCTTTGAACTCTGTATCACCTTCCCCATTAATGTTGTTACATCCACCTC
CACAATTATCTCCTTTCTTGCAACCACACGGTCAACAAGTTCCTTATTACTTGGAAAA
TGAACCATCAGGTTATACTGTCAGAGAAGCAGGTCCTCCAGCCTTTTACAGACCAAA
TTCCGATAACAGAAGACAAGGTGGTAGAGAAAGATTAGCTTCTACTAATGACAAAG
GTTCTATGGCTATGGAATCAGCAAAGGAAACAAGATATTGTGCCGTATGCAACGAT
TACGCTTCTGGTTATCATTACGGTGTTTGGTCATGTGAAGGTTGCAAAGCTTTCTTTA
AGAGATCTATCCAAGGTCACAATGATTATATGTGTCCAGCAACCAATCAATGCACTA
TTGACAAAAACAGAAGAAAGTCTTGTCAAGCCTGCAGATTGAGAAAGTGTTACGAA
GTTGGTATGATGAAAGGTGGTATTAGAAAGGATAGAAGAGGTGGTAGAATGTTGA
AACATAAGAGACAAAGAGATGACGGTGAAGGTAGAGGTGAAGTCGGTTCCGCTGG
TGACATGAGAGCAGCCAATTTGTGGCCTAGTCCATTGATGATCAAGAGATCTAAGA
AAAATTCTTTGGCATTGAGTTTAACCGCCGATCAAATGGTTTCTGCCTTGTTAGACG
CTGAACCTCCAATCTTATATTCAGAATACGATCCTACAAGACCATTCAGTGAAGCAT
CTATGATGGGTTTGTTAACCAATTTGGCCGACAGAGAATTGGTTCATATGATTAACT
GGGCAAAAAGAGTACCAGGTTTTGTTGATTTGACTTTACATGACCAAGTACACTTGT
TAGAATGTGCTTGGTTGGAAATCTTAATGATTGGTTTGGTTTGGAGATCTATGGAAC
ATCCTGGTAAATTGTTGTTCGCACCAAATTTGTTGTTGGATAGAAACCAGGGTAAAT
GTGTCGAGGGTATGGTAGAAATCTTCGACATGTTGTTGGCTACATCCAGTAGATTC
AGAATGATGAATTTGCAAGGTGAAGAATTTGTCTGCTTGAAGTCTATAATCTTGTTG
AACTCAGGTGTATACACATTTTTGTCTTCAACATTGAAGTCATTGGAAGAAAAGGAT
CATATCCACAGAGTTTTGGATAAGATCACTGACACATTGATCCATTTGATGGCTAAG
GCAGGTTTGACATTACAACAACAACACCAAAGATTGGCTCAATTGTTGTTGATCTTG
TCCCATATCAGACACATGAGTAATAAGGGTATGGAACATTTGTACTCTATGAAGTGT
AAGAACGTTGTCCCTTTGTACGATTTGTTGTTGGAAATGTTGGACGCTCATAGATTG
CACGCACCAACCTCCAGAGGTGGTGCTAGTGTTGAAGAAACTGATCAATCCCATTT
GGCCACAGCTGGTAGTACCTCCAGTCACTCATTACAAAAGTATTACATAACAGGTGA
AGCCGAAGGTTTCCCAGCAACAGTCTAATAA

ERECYC1

GAGCTCAAAGTCAGGTCACAGTGACCTGATCAAATCTAGAAGATCCAAAGTCAGGT
CACAGTGACCTGATCAAACTCGAGCAGATCCGCCAGGCGTGTATATATAGCGTGGA
TGGCCAGGCAACTTTAGTGCTGACACATACAGGCATATATATATGTGTGCGACGAC
ACATGATCATATGGCATGCATGTGCTCTGTATGTATATAAAACTCTTGTTTTCTTCTT
TTCTCTAAATATTCTTTCCTTATACATTAGGACCTTTGCAGCATAAATTACTATACTTC
TATAGACACGCAAACACAAATACACACACTAATCTAGA

Bold regions in ERECYC1 are estrogen response element sequences.
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2009) following the manufacturer’s protocol. Successful construct of pHO-GPDp-CYC1t-KanMX4HO was verified through PCR and gel electrophoresis.
For yeast genomic integration and expression of hER genes, hER-y and hER-wt were inserted
between the GPDpromoter and CYC1terminator of pHO-GPDp-CYC1t-KanMX4-HO plasmid respectively
(Fig 4.2). Specifically, pHO-GPDp-CYC1t-KanMX4-HO was firstly linearized at the polylinker region
by PCR amplification with P424_BamHI_F and P424_EcoRI_R primers. Then primers pairs
ohER_gib_HO_F, ohER_gib_HO_R and shER_gib_HO_F, shER_gib_HO_R were used to amplify
hER-y and hER-wt respectively. Each primer contains tail sequence overlapping the ends of the
linearized pHO-GPDp-CYC1t-KanMX4-HO. PCR amplified hER-y and hER-wt were gel-purified and
assembled to linearized pHO-GPDp-CYC1t-KanMX4-HO by Gibson Assembly, producing two
integration vectors pHO-GPDp-hERy-CYC1t-KanMX4-HO and pHO-GPDp-hERwt-CYC1t-KanMX4HO.
Site-directed mutagenesis of wild type human estrogen receptor alpha gene
To obtain mutants of hER-wt gene, site-directed mutagenesis were performed with Q5 SiteDirected Mutagenesis Kit (New England Biolabs, Ipswich, MA) following the manufacturer’s
protocol. The pHO-GPDp-hERwt-CYC1t-KanMX4-HO plasmid was used as the template for hER
mutagenesis. Five mutations Asp351Tyr, Glu353Val, Met396Val, Leu525Ala, and Asp538Gly were
generated on the integration plasmid respectively. All mutations were verified by sequencing.
The oligonucleotides used in the mutagenesis are listed in Table 4.4.
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Fig 4.2. Schematic of hER gene expression cassette and genomic integration. hER gene was
inserted into p424GPD between the GPD promoter and CYC1 terminator. The whole expression
cassette was than inserted into the pHO-poly-KanMX4-HO plasmid. Than the fragment from HOL
to HOR was PCR amplified and integrated into yeast genome through homologous recombination
at the HO locus.

123

Table 4.4 Oligonucleotides used for human estrogen receptor alpha site-directed mutagenesis
Primer name

sequence

sHER_Asp351Tyr_F

CAATTTGGCCtacAGAGAATTGG

sHER_Asp351Tyr_R

GTTAACAAACCCATCATAGATG

sHER_Glu353Val_F

GCCGACAGAGtATTGGTTCATATG

sHER_Glu353Val_R

CAAATTGGTTAACAAACCCATC

sHER_Met396Val_F

TTGGAGATCTgTGGAACATCC

sHER_Met396Val_R

ACCAAACCAATCATTAAGATTTC

sHER_Leu525Ala_F

TATGGAACATgcgTACTCTATGAAGTG

sHER_Leu525Ala_R

CCCTTATTACTCATGTGTC

sHER_Asp538Gly_F

CCCTTTGTACggtTTGTTGTTGG

sHER_Asp538Gly_R

ACAACGTTCTTACACTTCATAG
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Genomic integration and expression of hERα and mutant genes in yeast
The constructed integration plasmid pHO-GPDp-CYC1t-KanMX4-HO carries sequences
homologous to the HO locus of S. cerevisiae genome, allowing single-copy genomic integration
into the same HO locus through homologous recombination(Voth, Richards et al. 2001). hER-y,
hER-wt, and hER mutants are all expressed by the same GPD promoter and CYC1 terminator,
making strains carrying hER variants easily comparable.
To perform the integration, pHO-GPDp-CYC1t-KanMX4-HO carrying either hER-y, hER-wt or hER
mutants were PCR amplified from HOL to HOR region with HO_F and HO_R primers. PCR products
were then directly transformed into S. cerevisiae BY4742 following the LiAc/ssDNA/PEG method
previously described(Gietz and Schiestl 2007). Transformants were selected on the
aforementioned YPD agar plates with G418 antibiotic selection. Genomic integration was verified
by genomic DNA PCR amplification and gel electrophoresis. Expression of hER was further verified
by reverse transcriptase PCR.
Construction of integration plasmid pS20-EREMEL1-Lux
pEREMEL1-Lux is a self-replicative plasmid contains estrogen response element (ERE) fused MEL1
promoter, which can trigger the expression of downstream light-producing luxCDABE genes
when bounded by activated estrogen receptor proteins.
To allow genomic integration of this bioluminescent reporter plasmid, the 2µ element
responsible for plasmid self-replication within the yeast host was replaced by a 1.6kb DNA
amplified from yeast genome (Fig 4.1), which not only disrupted the self-replicative feature of
the plasmid, but also provided homologous sequence, making genomic integration feasible. The
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locus of the 1.6 kb DNA was located at Chromosome XVI and was chosen based a previous study
characterizing efficient chromosomal integration sites for heterologous gene expression in
yeast(Dongmei Bai, Verena et al. 2009). For convenience purpose, the 1.6 kb DNA was named as
S20. To replace the 2µ with S20, PCR was performed on pEREMEL1-Lux using S20_pERE_F and
S20_pERE_R primers, which produced linearized pEREMEL1-lux without the 2micron element,
and also added overlapping sequence to the S20. S20 was PCR amplified from yeast genomic DNA
with 20_up_F and 20_down_R primers and then assembled to the linearized plasmid by gibson
assembly, generating pS20-EREMEL1-Lux.
Construction of bioluminescence reporter vector pERECYC1-lux
pERECYC1-Lux was generated by replacing the promoter EREMEL1 in the pEREMEL1-Lux plasmid
with the ERECYC1 sequence (Fig 4.1). ERECYC1 sequence was an estrogen response element
fused CYC1 promoter successfully used in a previously developed yeast estrogen bioassay(Toine,
Richard et al. 2004). The ERECYC1 DNA was synthesized by Genscript (Piscataway, NJ), and the
sequence is presented in Table 4.3.
pEREMEL1-Lux was linearized by PCR amplification with pERE_Up_pro and pERE_Down_pro
primers, which excluded the EREMEL1 region. Synthesized ERECYC1 DNA was then PCR amplified
with ERECYC1_F+pERE and ERECYC1_R+pERE primers which also added tail sequences
overlapping the linearized pEREMEL1 plasmid. ERECYC1 was then assembled to the linearized
plasmid by gibson assembly, generating pERECYC1-Lux. Successful ligation was verified by
sequencing.
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Transformation and construction of yeast estrogen bioluminescent reporters
Yeast strains carrying hER-y and hER-wt were transformed with pERECYC1-lux, pEREMEL1-lux and
pS20-EREMEL1-lux respectively following the previously described method (Gietz and Schiestl
2007). Prior to yeast transformation, pS20-EREMEL1-lux was linearized at the middle of the S20
region by PCR with 20-up_R and 20-down_F primers, allowing genomic integration at the S20 site
of yeast chromosome XVI. Yeast strains carrying hER mutants were transformed with pERECYC1lux only. Transformed yeast colonies were selected on YSD(-ura) agar plate and then maintained
on YSD (-ura, G418) agar plate. All strains constructed are listed in Table 4.5.
Bioreporter strain performance evaluation
To test the constructed strains’ response time to estrogen and quantitative luminescence, 10 µL
of 10E-6 M 17β-estradiol in methanol were pipetted to 96 well plate and air-dried. Then a fresh
colony of each strain was picked and diluted into YSD (-ura) liquid medium to reach OD600 ~0.5.
Then 100 µL of the diluted culture were added to each well of the 96-well plate. Negative controls
(yeast culture without estrogen added) were included for each strain and the exposure were
conducted in triplicate. To evaluate the EC50 of 17β-estradiol for each strain, each strain was
grown overnight at 28°C, 200 rpm from fresh colony until OD600 reached ~0.8. Before the test, 10
uL of serial diluted 17β-estradiol in methanol were added into the 96-well plate and allowed airdried. Then 100 uL of yeast culture was added into each well. Bioluminescence was measured by
BioTek Synergy2 Multilabel reader, with default gain setting of 135, integration time of 1 s/well.
Experiment was performed in triplicate. Solvent blanks (cell+medium+solvent) and true blanks
(cell+medium) were included as negative controls.
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Table 4.5 Constructed Saccharomyces cerevisiae bioluminescent estrogen reporters
Strain Name

Form of reporter
plasmid

Form of
hERα

ERy-pMEL

pEREMEL1-lux

hER-y

ERy-pCYC
ERy-inteMEL

pERECYC1-lux

hER-y

pS20-EREMEL1-lux

hER-y

(integrated)

hERα mutations

Lys362Glu,
Asn413Asp,
extra 20 AA
residues

ERwt-pMEL

pEREMEL1-lux

hER-wt

Wild type

ERwt-pCYC

pERCYC1-lux

hER-wt

Wild type

ERwt-inteMEL

pS20-EREMEL1-lux
(integrated)

hER-wt

Wild type

ER351-pCYC

pERECYC1-lux

hER-351

Asp351Tyr

ER353-pCYC

pERECYC1-lux

hER-353

Glu353Val

ER396-pCYC

pERECYC1-lux

hER-396

Met396Val

ER525-pCYC

pERECYC1-lux

hER-525

Leu525Ala

ER538-pCYC

pERECYC1-lux

hER-538

Asp538Gly

hER-wt: wildtype 595 amino acids human estrogen alpha
hER-y: human estrogen receptor alpha in S. cerevisiae BLYES strain(Sanseverino, Gupta et al. 2005).
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Data analysis
Chemical exposure response was considered significant when the bioluminescence increase was
higher than three times the background bioluminescence standard deviation (3-sigma rule,
p<0.003). To calculate the EC50 of 17β-estradiol for each strain, bioluminescence reading were
plotted against the log concentration, generating a sigmoidal curve. EC50 of each test was
calculated using the 4 variables sigmoidal curve fitting function in GraghPad Prism 5.0 (GraphPad
Software, La Jolla, California).

4.2.2 Results and Discussions
Response time and dynamic range of hER-y and hER-wt bioreporter strains
A goal of this study was to create comparable bioreporters strains expressing hER mutant genes.
Therefore it was necessary to firstly establish proper constructs that deliver stable and
comparable performance in estrogen detection. The original BLYES previously developed have
been extensively used in many applications including potential estrogenic compound screening,
creek water, wastewater, sludge, soil testing, etc(Wang, Eldridge et al. 2015). However the
genetic background of the strain wasn’t informed in the literature. Therefore S. cerevisiae BY4742
strain was chosen as the new host for bioreporter construction. The hER gene chromosomally
integrated in the BLYES strain (designated as hER-y) was cloned and initially used as the wild type
for new bioreporter construction. Nevertheless, sequencing revealed that hER-y contains two
missense mutations (Lys362Glu, Asn413Asp), as well as an extra 20 amino acids fragments at the
AF-1 domain that wasn’t reported in previous literature and database yet (Fig 4.3). Therefore a
true wild type, the 595 amino acids hER-wt gene, was synthesized and used in this study.
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Fig 4.3. Translated hER-y sequence aligned with wildtype estrogen receptor sequence. The hERy protein contain extra 20 amino acids (marked in red box), as well two missense mutations
Lys362Glu, Asn413Asp.
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Two plasmids sharing the same lux genes except the ERE fused promoter, pEREMEL1-lux and
pERECYC1-lux, were evaluated for their bioluminescence production with hER-y and hER-wt
respectively. Besides, single-copy genomic integration of pS20-EREMEL1-lux was also tested for
bioluminescence production performance. A total of six strains were generated based on the S.
cerevisiae BY4742 strain, as listed in Table 4.5.
To determine the performance of hER-wt and hER-y bioreporter strains, natural estrogen 17βestradiol was used as the standard chemical to verify proper ligand-receptor interaction and
transcriptional activation, as well as to evaluate the response time and the dynamic range of
bioluminescence output. All 6 strains were exposed to 1E-7 M of 17β-estradiol, a saturation
concentration at which estrogen bioreporters produce the maximum response according to
previous studies (Toine, Richard et al. 2004, Sanseverino, Eldridge et al. 2009). Bioluminescence
monitored throughout 24 hours was plotted in Fig. 4.4. All six strains showed no background
bioluminescence when no estrogen was present; the background bioluminescence was
indistinguishable from the background reading of the blanks. Significant bioluminescence
response was detected after 1 hour of estrogen exposure for ERwt-pMEL, ERy-pMEL, ERy-pCYC
strains, though the signals were low. After two hours, ERwt-pCYC and ERy-inteMEL strains
produced significant bioluminescence as well. ERwt-inteMEL strain failed to produce detectable
bioluminescence throughout the whole exposure experiment, while ERy-inteMEL strain
produced detectable yet very weak bioluminescence response with the maximum output
averaging 146.3 counts/s. hER-y based strains ERy-pMEL and ERy-pCYC produced the maximum
bioluminescence at the 12th hour, with averages of 43453.2 and 25999.8 counts/s respectively.
In comparison, hER-wt based ERwt-pCYC produced maximum bioluminescence at the 11th hour
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Fig 4.4. Time course response of six estrogen bioreporters to 1E-7 M of 17β-estradiol. (Mean and
standard deviation, n=3)
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with an average of 9567.5 counts/s; ERwt-pMEL strain produced maximum response at the 10th
hour with an average of 6615 counts/s. These results together indicate these strains have similar
response time to 17β-estradiol, yet the dynamic range of light output differs considerably.
When ERy-pMEL and ERwt-pMEL strain were initially constructed, hER-y based ERy-pMEL
produced significantly higher maximum bioluminescence than hER-wt based ERwt-pMEL strain.
To determine whether this difference was the result of the sequence difference between hER-y
and hER-wt, the promoter of pEREMEl1-lux was replaced by a previously developed ERE fused
CYC1 promoter(Toine, Richard et al. 2004), generating the pERECYC1-lux plasmid. As
demonstrated in Fig 4.4, ERy-pCYC1 strain still produced much higher maximum bioluminescence
upon exposure to 17β-estradiol compared to the ERwt-pCYC1 strain. Additionally, for the two
strains with integrated pS20-EREMEL1-lux (ERy-inteMEL and ERwt-inteMEL), ERy based strain
was able to produce detectable light output while the ERwt based strain could not. These findings
together confirmed that hER-y gene was responsible for the higher bioluminescence production.
Sequencing of hER-y revealed that hER-y gene contained two missense mutations (Lys362Glu,
Asn413Asp), as well as an extra 20 amino acid residues fragment in the DNA binding domain (Fig
4.3). BLAST in NCBI database did not demonstrate any previous record regarding this extra
fragment. Whether the elevated bioluminescence production was the result of the mutations or
the extra fragment requires further investigation.
The purpose of constructing ERwt-inteMEL and ERy-inteMEL strains with chromosomally
integrated bioluminescence plasmid was to allow all the bioreporters having identical number
(single copy) of bioluminescence production cassettes, which can minimize the variables when
comparing strains carrying different hER mutations. However the potential risk of such
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construction is that low copy number of bioluminescence genes in the yeast cell may not be able
to produce sufficient level of signal. This may explain why in this study, ERwt-inteMEL strain failed
to produce detectable bioluminescence. Although hER-y based strain ERy-inteMEL produced
detectable signal with the integrated pEREMEl1-lux, the light output was also too weak to be
applicable for the downstream mutagenesis comparison study.
Half-maximal effective concentration (EC50) of hER-y and hER-wt based estrogen bioreporters
EC50 is the primary metric used to quantify and compare the potency of estrogenic compounds
to activate with estrogen receptor. Therefore to determine which bioreporter construct to be
used for the downstream mutagenesis study, EC50 of all six strains in exposure to 17β-estradiol
were compared. Overnight culture (in 2% glucose YSD -ura medium) of the six hER-y and hER-wt
based strains were exposed to serially diluted 17β-estradiol and bioluminescence was monitored
every hour. Except for the two strains that have pEREMEL1-lux integrated in the genome (ERyinteMEL and ERwt-inteMEL), all other four strains produced detectable bioluminescence and a
peak response at 6 hours then decreased. Therefore the 6th hour bioluminescence was plotted
against the log concentration of 17β-estradiol (Fig 4.5). All four strains produced sigmoidal
exposure curves at this time point. Similar to the previous test, ERy-pMEL demonstrated higher
dynamic range, with maximum light output reaching ~8000 counts/s. ERwt-pCYC and ERy-pCYC
showed slightly smaller dynamic range, with maximum bioluminescence peaking at averages of
5186 and 4613 counts/s respectively. ERwt-pMEL, produced a weaker response in this test, with
maximum bioluminescence averaging 2085 counts/s. The EC50 of 17β-estradiol for each of the
four strains were calculated and listed in Table 4.6. The EC50 of ERwt-pMEL, ERwt-pCYC and
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Table 4.6. Half-maximal effective concentration (EC50) of 17β-estradiol for each strain through
curve fitting

EC50 (M)

ERwtpMEL

ERy-pMEL

ERwt-pCYC

ERy-pCYC

ERwtinteMEL

ERyinteMEL

5.86E-09

9.35E-10

3.71E-09

1.16E-09

-

-

0.97

1.00

0.98

0.99

-

-

R2
(curve
fitting)
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ERy-pCYC were all in the 10E-9 molar range, while the ERy-pMEL showed slightly lower EC50 of
10E-10 range.
For downstream hER mutagenesis study, ERwt-pCYC was chosen as the wildtype base strain for
its maximum bioluminescence response and EC50 in exposure to 17β-estradiol. ERwt-pCYC was
also favored as the ERE fused CYC1 promoter was successfully used in yeast GFP based estrogen
bioreporters in previous studies (Bovee, Helsdingen et al. 2004, Toine, Richard et al. 2004).
Optimization of ERwt-pCYC strain based chemical bioassay
One phenomenon that was found for all the constructed strains including the ERwt-pCYC was
that for overnight cultures grown with 2% glucose YSD medium, the bioluminescence of 17βestradiol exposure quickly reached the maximum at 6 hours and then drastically declined. The
bioluminescence output of these strains was much shorter compared to S. cerevisiae BLYES,
whose maximum bioluminescence lasts at least 12 hours(Sanseverino, Gupta et al. 2005). Since
ERwt-pCYC was chosen for the new estrogen reporter base construct, it was necessary to extend
the response time to optimize the chemical exposure bioassay due to the assay format and utility
in data analysis. Considering that GPD promoter and CYC1 terminator was used for hER
expression, a further literature search revealed a previous finding that the performance of yeast
GPD promoter can be significantly suppressed by limiting glucose concentration in the
culture(Siavash, Verena et al. 2010). To test whether glucose content was causing the altered
bioluminescence response, an overnight culture of ERwt-pCYC with OD 1.64 was 1:2 diluted by
YSD (-ura) media with 2%, 4% and 6% (w/v) of glucose. Diluted culture was then exposed to serial
diluted 17β-estradiol and bioluminescence reading was recorded at each hour for 24 hours. The
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maximum bioluminescence of the diluted ERwt-pCYC culture was clearly enhanced by the
presence of added fresh medium (Fig 4.6). Compared to non-diluted culture, all diluted cultures
showed significantly higher bioluminescence response. When comparing the cultures diluted
with different glucose concentration, 2% glucose YSD diluted culture reached peak
bioluminescence at 11 hours, while 4% glucose YSD diluted culture maintained bioluminescence
to 18 hours. The culture diluted with 6% glucose YSD maintained the increase of bioluminescence
till 24 hours, however its maximal light output was lower compared to the 4% glucose YSD diluted
culture from 7 to 18 hours.
The EC50s of 17β-estradiol for the original and diluted cultures were also calculated for each hour
once a full sigmoidal response curve was present (Fig 4.7). The EC50 of all diluted culture were
within the 10E-9 M range. 2% and 4% glucose YSD diluted cultures demonstrated similarly stable
EC50 throughout the monitoring period, with the EC50 gradually shift towards the lower 10E-9M
range. Based on the test results, 4% glucose YSD were chosen as the media for yeast bioassay
with 1:2 dilution before chemical exposure.
To test whether this modified protocol can yield EC50, 17β-estradiol standard exposure tests
were repeated six times using different batch of ERwt-pCYC culture (Fig 4.8). The length of
exposure varied from 12 to 15 hours in these tests, and the EC50 ranged from 0.96E-9 M to 5.79E9 M, with an average of 2.44E-9 M and standard deviation of 1.95E-9 M, suggesting that the
ERwt-pCYC strain and the modified protocol is capable of evaluating estrogenic compounds
reliably and reproducibly.
Compared to the previously constructed lux-based bioreporter S. cerevisiae BLYES, which was
reported with EC50 of (2.4±1.0)E-10 M for 17β-estradiol, ERwt-pCYC strain demonstrated lower
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Fig 4.6. Maximum bioluminescence of 1:2 diluted ERwt-pCYC overnight culture in YSD medium
with different glucose concentration.
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Fig 4.7. EC50 of 1:2 diluted ERwt-pCYC overnight culture in YSD medium with different glucose
concentration.
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Fig 4.8. Range of EC50 of 17β-estradiol responded by ERwt-pCYC strain. Triangles are each data
point. Bars are the mean and standard deviation.
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sensitivity, with average EC50 of 17β-estradiol about one magnitude less than that of
BLYES(Sanseverino, Gupta et al. 2005). Considering the molecular constructs of ERwt-pCYC and
BLYES strain are different on several aspects, i.e. the design/layout of bioluminescent plasmid,
estrogen receptor and its expression cassette etc., the potential cause of ERwt-pCYC’s reduced
sensitivity requires further investigations. Yet the performance of the ERwt-pCYC strain was
adequate for the purpose of this study, for the strain demonstrated zero background
bioluminescence, good reproducibility with reliable level of sensitivity.

4.3. Evaluating hERα Mutants’ Response to Putative Estrogenic EDCs.
With ERwt-pCYC strain selected as the wild type hERα bioreporter, 5 mutant strains, each
carrying a missense mutation at hERα ligand binding domain and the same pERECYC1-lux plasmid,
were used to evaluate how these mutations alter the response of estrogen receptor to different
EDCs. A total of 12 estrogenic compounds, including natural estrogen, synthetic estrogens,
phytoestrogens, and industrial chemicals were evaluated by these strains.

4.3.1 Materials and Methods
Chemical dilutions
All tested estrogenic compounds including the structure and CAS registry number are listed in
Table 4.1. To perform the chemical exposure bioassay, E2, DES, 4-nonylphenol, bisphenol-A,
tamoxifen, EE2, mestranol, resveratrol, S-Equol were dissolved in distilled methanol. Genistein,
daidzein and coumestrol were dissolved in dimethyl sulfoxide (DMSO). All chemicals were initially
prepared at 1E-2 M concentration, and diluted 1:2 for twice, yielding the 5E-3 M and 2.5E-3M
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dilution. Then each of the three dilutions were 1:10 serial diluted for 8 times, making the final
dilutions ranging from 1E-2 to 2.5E-11 M.
Strain, culture condition
Six genetically engineered S. cerevisiae bioluminescent reporter strains, ERwt-pCYC, ER351-pCYC,
ER353-pCYC, ER396-pCYC, ER525-pCYC and ER538-pCYC were used in this comparison study
(Table 4.5). On the day before chemical test, each culture was started from a fresh colony in 5
mL of 4% glucose YSD (-ura) liquid medium and grown overnight at 28 °C, 200rpm until reaching
OD 1.0. The culture was then 1:2 diluted in 4% glucose YSD (-ura) medium prior to chemical
exposure.
Chemical exposure bioassay
For chemicals soluble in methanol, 10 µL of each serial dilution were placed in each well of the
white 96 well plate and air-dried. For chemicals dissolved in DMSO, 1 µL of each serial dilutions
were added into each well of the white 96 well plate. Then 100uL of 1:2 diluted yeast culture was
added to each well to initiate the chemical exposure. For each test, solvent blanks
(cell+medium+solvent) and true blanks (cell+medium) were included as negative controls. Each
chemical were tested by all the six yeast estrogen bioreporters on the same day. Chemical
bioassays were performed in three biological replicates, and each with two technical replicates.
Loaded 96-well plates were covered with sealing films and incubated at 28 °C for 15 hours.
Bioluminescence was measured by BioTek Synergy2 Multilabel reader, with default gain setting
of 135, integration time of 1 s/well.
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Data analysis
Chemical exposure response was considered significant when the bioluminescence increase is
higher than three times of the background bioluminescence standard deviation (3-sigma rule,
p<0.003). To calculate the EC50 of each chemical for each strain, bioluminescence readings were
plotted against log concentration. EC50 of each chemical for each biological replicate was
calculated using four-parameter dose-response curve fitting in GraphPad Prism 5.0 (GraphPad
Software, La Jolla, California). To determine the significance of difference between the chemical
responses of wild-type strain and mutant strain to each ligand, Student’s t-test was performed
using log EC50 values from each test.
Two way hierarchical clustering was performed using ClustVis(Metsalu and Vilo 2015). Average
EC50 values from the yeast assay were –log transformed and missing values were filled with 0.01
prior to the clustering. For hierarchical clustering, rows were centered; unit variance scaling was
applied to rows. Both rows and columns were clustered using correlation distance and Ward
linkage.

4.3.2 Results and Discussion
To determine whether hER mutations have altered responses to different estrogenic EDCs, yeast
based estrogen receptor bioreporter assay was selected as the platform to evaluate
transcriptional activation triggered by ligand activated estrogen receptor. With ERwt-pCYC strain
selected as the wild type hERα bioreporter, 5 mutant strains, each carrying a missense mutation
at hERα ligand binding domain and the same pERECYC1-lux plasmid, were used to evaluate how
these mutations modulate the response of estrogen receptor to different EDCs. A total of 12
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estrogenic compounds, including natural estrogen, synthetic estrogens, phytoestrogens, and
industrial material were evaluated by these strains. EC50 of all tested chemicals for each hER
yeast reporter are presented in Table 4.7 and Fig 4.9. The dose-response curves for all tested
chemicals are presented in Fig 4.10.
Response of wildtype bioreporter ERwt-pCYC to 12 estrogenic EDCs
The wildtype bioreporter produced quantifiable response to all the tested estrogenic compounds
except for daidzein (detectable yet non-reportable response was observed) (Fig 4.11, Table 4.7).
Among these estrogenic compounds, natural estrogen E2 and synthetic estrogen EE2 triggered
the strongest response, with EC50 of (1.51±0.32)E-09 M and (9.68±1.06)E-10 M respectively, the
lowest among all the tested chemicals. Synthetic hormones DES and mestranol, and the
phytoestrogen coumestrol also triggered lower and moderately strong responses, with EC50
ranging from (8.67±1.99)E-09, (3.93±1.28)E-08 to (5.78±0.84)E-08 M respectively. Although
daidzein exposure produced weak non-reportable response, its biotransformed product S-equol
triggered significantly higher response with EC50 of (1.10±0.36)E-06 M. Another phytoestrogen
genistein showed similar level of EC50 of (1.45±0.10)E-06 M. The two widely used industrial
compounds nonylphenol and BPA produced relatively weak response with EC50 of (3.87±0.79)E06 and (1.05±0.21)E-05 M respectively. The selective estrogen receptor modulator tamoxifen
exhibited weak estrogenic response as well, yielding EC50 of (1.36±0.12)E-05 M.
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Table 4.7. Half-maximal effective concentration (EC50) of 12 estrogenic compounds evaluated by
wild type and mutant hERα yeast estrogen bioreporters
Wildtype

Asp351Tyr

Glu353Val

Met396Val

Leu525Ala

Asp538Gly

(mol/L)

(mol/L)

(mol/L)

(mol/L)

(mol/L)

(mol/L)

E2

(1.51±0.32)
E-09

(5.09±0.60)
E-09*

(1.90±0.26)
E-06*

(1.69±0.81)
E-09

(3.82±1.03)
E-08*

(1.14±0.04)
E-09

EE2

(9.68±1.06)
E-10

(2.49±0.03)
E-09*

(3.36±0.27)
E-07*

(7.11±0.18)
E-10

(2.12±0.46)
E-08*

(4.01±0.74)
E-09*

DES

(8.67±1.99)
E-09

(1.08±0.12)
E-07*

(3.36±0.45)
E-05*

(8.09±2.12)
E-09

(2.36±0.51)
E-07*

(1.24±0.16)
E-08*

Mestranol

(3.93±1.28)
E-08

(2.12±0.10)
E-06*

(1.99±0.16)
E-06*

(2.39±0.47)
E-08

(3.07±0.36)
E-05*

(9.21±1.69)
E-09*

Tamoxifen

(1.36±0.12)
E-05

-

-

(1.08±0.11)
E-05

n.r

(2.50±0.17)
E-05*

Daidzein

n.r

-

-

n.r

-

(1.13±0.06)
E-05*

S-equol

(1.10±0.36)
E-06

-

-

(1.39±0.63)
E-06

-

(1.18±0.08)
E-07*

Genistein

(1.45±0.10)
E-06

n.r

-

(1.21±0.25)
E-06

n.r

(2.23±0.06)
E-07*

Coumestrol

(5.78±0.84)
E-08

(2.77±0.23)
E-06*

-

(6.27±0.38)
E-08

-

(3.76±0.34)
E-08*

Resveratrol

(9.14±0.45)
E-05

-

-

(7.85±0.74)
E-05

-

(1.26±0.17)
E-04*

Nonylphenol

(3.87±0.79)
E-06

-

-

(3.78±0.07)
E-06

(3.88±0.22)
E-05*

(1.70±0.03)
E-07*

BPA

(1.05±0.21)
E-05

n.r

-

(8.27±1.22)
E-06

(1.28±0.12)04*

(3.52±0.62)
E-06*

Results are expressed as mol/L concentration (mean ± SD for biological triplicates). Results indicated with * are
mutant responses that are significantly different from the wild type response (Student’s t-test, using –log values,
p<0.05). “n.r”: detectable response but EC50 non-reportable. “-”: no detectable response.
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Fig 4.9. EC50 of 12 ligands evaluated by wildtype and mutant hERα yeast estrogen bioreporters.
(Values presented as mean ± SD obtained from biological triplicate. *: p<0.05)
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Fig 4.10. Dose-response curves of 12 tested ligands evaluated by wildtype and mutant hERα yeast
estrogen bioreporters. (Values are presented as mean±SD, n = 6, dose-response curves are fitted
4 parameters logistic curves.)
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Fig 4.11. Wildtype ERwt-pCYC strain’s EC50 response to 12 estrogenic compounds
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Response of mutant strains ER351-pCYC, ER353-pCYC, ER396-pCYC, ER525-pCYC, ER538-pCYC
to 17β-estradiol
The effect the five hERα mutations were firstly evaluated by exposing the mutant carrying yeast
bioreporters to serial diluted natural estrogen 17β-estradiol. The dose response curves of the
wildtype and mutant yeast bioreporters are shown in Fig 4.12. EC50 values for each bioreporter
are presented in Fig 4.13 and Table 4.7.
Among the five mutants, three of them demonstrated statistically different responses to 17βestradiol compared to the wildtype. Asp351Tyr mutant demonstrated moderately reduced
response, reporting EC50 of (5.09±0.60)E-09 M, compared to the wildtype’s EC50 of
(1.51±0.32)E-09 M. Glu353Val demonstrated the weakest response, reporting EC50 of
(1.90±0.26)E-06 M, three magnitude lower than the wildtype. Leu525Ala also demonstrated
considerable decrease in the response, with EC50 of (3.82±1.03)E-08, about one magnitude lower
than the wildtype. Two of the mutants, Met396Val and Asp538Gly reported EC50 of
(1.69±0.81)E-09 M and (1.14±0.04)E-09 M respectively, which had with no statistical significance
compared to the wildtype.
Response of Asp351Tyr mutant to estrogenic EDCs
As Asp351Tyr mutant bioreporter resulted in reduced response to E2 compared to the wildtype,
this mutation also consistently resulted in significantly decreased responses when exposed to the
other 11 tested estrogenic EDCs (Table 4.7). For less potent compounds including nonylphenol,
S-equol, tamoxifen, daidzein and resveratrol, no detectable response was present. When
exposed to genistein and BPA, Asp351Tyr mutant produced detectable yet not strong enough
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Fig 4.12. Dose-response curve of hERα wildtype and mutant yeast bioreporters to serial diluted
17β-estradiol. Values are Mean±SD, n=6.
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Fig 4.13. EC50s of hERα wildtype and mutant bioreporters in response to 17β-estradiol.
(Mean±SD, ***: p<0.001)
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response to properly report EC50. EE2 exposure produced the strongest response, with EC50 of
(2.49±0.03)E-09 M, slightly lower than the wildtype EC50 of (9.68±1.06)E-10 M. DES, mestranol
and coumestrol exhibited sharper decrease in the response, with the EC50 of DES shifted about
1 magnitude, mestranol and coumestrol shifted around 2 magnitude.
Asp351Tyr was initially identified as a natural point mutation in an antiestrogen resistant
(tamoxifen-stimulated) human breast tumor cell line(Wolf and Jordan 1994). Several studies have
found that Asp351Tyr mutation can change the behavior of antiestrogens including tamoxifen
and raloxifene from antagonistic to agonistic and trigger estrogenic responses (Catherino and
Jordan 1995, Catherino, Wolf et al. 1995, Levenson, Catherino et al. 1997, Levenson and Jordan
1998). Asp351Tyr is located close but not inside the binding pocket. Previous studies have
suggested that Asp351 residue could be involved in stabilizing Helix-12 of hER ligand binding
domain to seal the binding pocket so that the estrogen receptor can be activated. Mutating
Asp351 to Tyr changes the side chain from negative charged to hydrophobic, which could reduce
its interaction with Helix12, making helix 12 less prone to the closed position, hence causing
reduced transcriptional activity. This may explain why in this yeast bioreporter, all tested
chemicals exhibited reduced EC50.
Response of Glu353Val mutant to estrogenic EDCs
Glu353 is the residue in hER ligand binding pocket responsible for ligand recognition and
providing electrostatic interaction with ligands including E2, EE2 etc. Previous studies
demonstrated that mutation of Glu353 will significantly reduce the binding affinity of E2, leading
to reduced receptor activation(Brzozowski, Pike et al. 1997, Ekena, Katzenellenbogen et al. 1998).
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In our study, 8 of the 12 tested ligands failed to produce any detectable response with Glu353Val
mutant. Only 4 ligands including E2, EE2, DES and Mestranol triggered significantly weaker
response compared to the wild type. Compared to the wildtype, the EC50 of EE2 sharply
increased from (9.68±1.06)E-10 M to (3.36±0.27)E-07M; DES and mestranol demonstrated
similarly inhibited responses, each had EC50 increased from (8.67±1.99)E-09 M to (3.36±0.45)E05 M and (3.93±1.28)E-08 M to (1.99±0.16)E-06 M, respectively.
Mutating Glu to Val changes the negatively charged side chain to hydrophobic side chain,
eliminating the potential electrostatic interaction between this residue and the ligand. Therefore
any ligand that relies on this interaction to properly dock into the binding pocket could suffer
from weaker binding. In our study, all tested ligands showed no or drastically reduced response,
suggesting that Glu353 residue plays pivotal role for effective binding by not only the natural
estrogen E2, but also other tested EDCs.
Response of Met396Val mutant to estrogenic EDCs
Met396Val mutation was initially identified on a primary breast cancer tumor, and no effect were
found by the time it was reported(Roodi, Bailey et al. 1995). Met396 residue does not reside in
the binding pocket, but is close to another critical residue Arg394. Since Met and Val both have
hydrophobic side chain, this mutation does not cause a significant change to the local
hydrophobic environment.
In this study, Met396Val mutant showed detectable responses to all 12 ligands at similar level as
the wild type (Table 4.7). No significant difference could be determined between the EC50 of
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Met396Val and that of wildtype for any of the 12 ligands, suggesting that Met396Val mutation
does not change the ligand binding and transcriptional activation of hERα.
Response of Leu525Ala mutant to estrogenic EDCs
Leu525 is a residue in the ligand binding pocket of hERα that can have direct contact with the
ligand. Previous study found that mutating the Leu525 to Ala can lead to inhibited estrogen
binding and transcriptional activity(Kirk, Karen et al. 1996). In this study, Leu525Ala mutant strain
did not respond to the weaker ligands including daidzein, S-equol, coumestrol, resveratrol.
Genistein, though less estrogenic than coumestrol when tested by the wildtype bioreporter,
produced weak detectable response by Leu525Ala mutant (Table 4.7). Tamoxifen also produced
weak detectable response, but EC50 was not reportable. E2, EE2, DES, nonylphenol and BPA
exposure all produced significantly decreased responses, with each EC50 increased ~ 1
magnitude than that of the wildtype. Leu525Ala mutation caused the most changes in response
to mestranol, which had EC50 increased ~3 magnitude, from (3.93±1.28)E-08 M to (3.07±0.36)E05 M. Overall, Leu525Ala mutation lead to inhibited response for all ligands compared to the
wildtype, suggesting that Leu525 plays an critical role in hERα’s ligand binding and transcriptional
activation function. Unlike other critical residues such as Glu353, Arg394, or His594, Leu525 has
a hydrophobic side chain and doesn’t provide electrostatic charge to the ligand. However Leu535
is positioned on the exit of the binding pocket, help shaping the binding cavity with its
hydrophobic sidechain. When Leu525Ala mutation occurs, this cavity is likely to be more open,
making ligands harder to stay/bind in the binding pocket. Depends on the shape of the ligand,
Leu525 may or may not be involved in the direct contact with the ligand. This may explain why
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Leu525Ala caused decreased transcriptional activity in the yeast reporter with different level of
reduction for different ligands.
Response of Asp538Gly mutant to estrogenic EDCs
In this study, Asp538Gly mutation caused both increased and decreased response to different
ligands (Table 4.7). When exposed to natural estrogen E2, Asp538Gly mutant showed similar
response compared the wild type, with the EC50 of (1.14±0.04)E-09 M versus (1.51±0.32)E-09 M
for the wild type. EE2, DES and tamoxifen triggered lower response in Asp538Gly mutant than
the wildtype, with EC50 shifted from (9.68±1.06)E-10 M to (4.01±0.74)E-09 M, (8.67±1.99)E-09
M to (1.24±0.16)E-08 M and (1.36±0.12)E-05 M to (2.50±0.17)E-05 M respectively. Interestingly,
for the rest of tested EDCs including mestranol, BPA, daidzein, S-equol, genistein, coumestrol,
and nonylphenol, Asp538Gly mutant produced significantly stronger response compared to the
wild type strain. Notable response increase was observed for nonylphenol and S-equol, whose
EC50 decreased from (3.87±0.79)E-06 M to (1.70±0.03)E-07 M and (1.10±0.36)E-06 M to
(1.18±0.08)E-07 M respectively, about 1 magnitude increase of activity. The response triggered
by daidzein increased from non-reportable response to EC50 of (1.13±0.06)E-05 M. Genistein
also produced significantly increased response with EC50 shifted from (1.45±0.10)E-06 M to
(2.23±0.06)E-07 M. BPA also posed significantly higher activity with Asp538Gly mutant, with EC50
shifted from (1.05±0.21)E-05 M to (3.52±0.62)E-06 M. Coumestrol demonstrated slightly
increased response with EC50 shifted from (5.78±0.84)E-08 M to (3.76±0.34)E-08M.
Asp538Gly mutation was initially identified in primary breast tumor tissue by a large-scale cancer
somatic mutation screening study and reported on COSMIC (Forbes, Bhamra et al. 2008, Kan,
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Jaiswal et al. 2010). Later studies discovered that Asp538 residue has relatively higher mutation
frequency in metastasis tumors (Alluri, Speers et al. 2014, Min, Aditya et al. 2014). The specific
mutation Asp538Gly was found associated with acquired endocrine therapy resistance
(tamoxifen resistance) in breast cancer patients who received long-term antiestrogen
therapy(Robinson, Wu et al. 2013). Through MD simulation and in vitro ERE-luciferase
mammalian bioreporters, previous studies suggested that this mutation force hERα binding
domain to maintain in agonist-binding conformation, rendering the estrogen receptor
constitutively active and hence causing anti-estrogen drugs ineffective. In our study, Asp538Gly
mutant yeast bioreporter did not demonstrate constitutive transcriptional activity, as no
constitutive bioluminescence were produced. Instead, Asp538Gly yeast bioreporter revealed an
unusual response profile to different tested EDCs. Out of the 12 tested ligands, only 4 of them,
E2, EE2, DES and resveratrol, elicited identical or reduced response compared to the wildtype,
whereas the rest of 8 ligands all exhibited elevated potency when been exposed to Asp538Gly
mutant. According to the finding of previous studies, Asp538Gly mutation could form hydrogen
bond with Asp351 residue, which could help and induce the helix-12 of hER ligand binding domain
to stay in the closed position. This stabilizing effect is likely to be responsible for the increased
potency of tested chemicals in the yeast bioassay. In this study, higher degree of response
increase was seen when less potent ligand was tested, suggesting the stabilizing effect makes
bigger impact for weak estrogen receptor ligands. The ligands showing significant elevated
potency with Asp538Gly mutant include common phytoestrogens, industrial compounds that are
easily accessible either passively or proactively in daily life. The fact that Asp538Gly mutation
causes elevated potency for these ligands in the yeast bioreporter raises health alert especially
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for breast cancer patients harboring this mutation in either the primary or metastatic tumors.
The advantage of yeast estrogen bioreporters is that estrogen receptor is the only nuclear
receptor present in the cell, eliminating possible interference from other nuclear receptors.
However although the yeast cell contains essential coregulators for estrogen receptor to properly
exert transcriptional activation, yeast doesn’t share the same cellular components as human cells.
Therefore further testing in mammalian cells and animal model is warranted to verify the
observed effect. In addition, special care should be taken in such tests when preparing the
medium/nutritious supplements, as weak estrogenic compounds present in the medium/food
could possibly cause unexpected estrogen receptor activation.
Comparison of hERα mutants’ response profile to estrogenic EDCs
To compare the response profile of each mutant strain to the 12 tested ligands, hierarchical
clustering was performed using the mean EC50 values obtained from the yeast bioassay (Fig 4.14).
In hierarchical clustering, the response pattern for the wildtype is closest to Met396Val, which is
in agreement with the finding that Met396Val didn’t cause altered response to all 12 compounds.
When comparing the response patterns for the other mutants, different mutation on hER
produced a different response profile to the 12 chemicals, suggesting that the degree of response
changes resulted from a mutation depends on the actual structure of individual EDC. E2 and the
two synthetic estrogen EE2 and DES clustered together, suggesting their similar response pattern
to the mutants. Compared to other weaker estrogenic EDCs, the response pattern of E2 was more
different, indicating that hER mutant’s response to E2 do not necessarily indicate similar response
to other estrogenic EDCs. This is particularly notable for Asp538Gly mutant, as E2 didn’t yield a
significantly different response to this mutant, yet other weaker estrogenic EDCs all yielded
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significantly stronger responses. These data together suggest that individual EDC testing for each
hER mutation variant is necessary, since response trend cannot be predicted from a single
chemical exposure. Considering that this study only tested 12 EDCs, it is reasonable to assume
that broader range of chemicals may also exhibit such discrepancy.
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Fig 4.14. Two-way hierarchical clustering and heatmap of EC50 for all 12 ligands and 6 yeast
bioreporters. Higher value represents higher potency (lower EC50 value). Two way hierarchical
clustering was performed using ClustVis(Metsalu and Vilo 2015). Average EC50 values from the
yeast assay were –log transformed and missing values were filled with 0.01 prior to the clustering.
For hierarchical clustering, rows were centered; unit variance scaling was applied to rows. Both
rows and columns were clustered using correlation distance and Ward linkage.
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Chapter 5. Conclusions and Future Perspectives
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The prevalence of EDCs in the environment and their health risks urge a thorough understanding
on the fate, transport and transformation of EDCs in the environment, and how they can affect
human and animal health. The studies in this dissertation were intended to add further
knowledge on these central topics of EDCs, and specifically focused on the application of yeast
bioluminescent reporters to study biotransformation of EDCs in wastewater treatment, and the
interaction between human estrogen receptor mutants and EDCs with both computational
modelling and experimental approach.
Chapter 2 demonstrated the use of the standardized yeast bioluminescent assays as a highthroughput screening tools to monitor the estrogenic, androgenic potencies and toxicity in the
wastewater treatment systems. To evaluate the sensitivity and reproducibility of the yeast assay
in wastewater monitoring, 7 days semi-continuous batch reactor experiments was conducted
using the activated sludge and raw wastewater spiked with hormones. Yeast bioreporter assay
successfully captured the rapid removal of estrogenic and androgenic activities in the bioreactors,
and also demonstrated good reproducibility and sensitivity. This standardized assay was then
applied in a 12 month comparative study on the wastewater effluent from the parallel-operated
MBR and TAS located at Powell, TN, USA. The yeast assay detected no significant androgenic
response in all tested TAS and MBR samples. While all TAS effluent samples and most (3 of the
31 dates) MBR effluent samples showed detectable estrogenic activity. The EEQ50 for TAS effluent
ranged from 21.61 ng/L to 0.04 pg/L and averaged 3.25 ng/L. For MBR, the effluent EEQ ranged
from 2.88 ng/L to 0.0134 pg/L and averaged ~10 fold less (0.32 ng/L) than TAS. Despite the large
temporal variation, the EEQ level in MBR effluent was consistently lower than that of TAS on any
given sampling day. Most MBR effluent samples also contained less cytotoxicity than TAS,
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suggesting that MBR can significantly reduce the release of EDCs and toxic compounds into the
environment. Correlation analysis was also conducted and revealed no significant correlation
between effluent EEQ level and WWTP operational parameters including MLSS, SRT, HRT and
BOD. This chapter also discussed the common issues in environmental sample testing caused by
sample toxicity, and suggested that EC20 could be a more appropriate metrics than EC50 in
environmental sampling. Overall, this chapter demonstrates with current state-of-the-art
wastewater treatment technology, trace level of EDCs are still been discharged into the aquatic
environment continuously. This chapter also suggests that the yeast bioluminescent assay is
suitable to serve as a sensitive, high-throughput, rapid and low-cost EDCs screening tool for
routine wastewater monitoring purpose.
Chapter 3 and 4 investigated the interaction of environmental EDCs with five human estrogen
receptor mutants at molecular level through computational modelling and experimental bioassay.
These mutations are either inside or close to the ligand binding pocket of the protein, and were
selected from cancer mutations database and previous literature. Chapter 3 specifically
examined the interaction of the in silico wildtype and mutant model with 29 selected
environmental EDCs. Ensemble docking of selected MD conformations of wildtype hERα ligand
binding domain showed moderate correlation with previous experimental binding assay data,
suggesting a relatively good performance of the docking scheme, especially considering the
evaluated ligands were strong to medium ER binders. When comparing the docking results
between hERα wildtype and the five mutants, ensemble docking simulation predicted decrease
of binding affinity for nearly all 29 ligands when the tested five hERα mutations occur. Among
the five hER mutations, Glu353Val was predicted to yield the highest reduction of binding affinity,
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while Leu525Ala was predicted to yield the least reduction, with some ligands demonstrated no
change or slightly increase in binding affinity. The study in chapter 3 was attempting to test
whether computational modelling can provide informative guidance for experimental testing of
estrogen receptor mutants’ response to EDCs. In this study, the difference between 2B1Z
wildtype and mutant docking scores was very modest, the accuracy of the predictions requires
further validation through experimental mutagenesis study.
In chapter 4, a new yeast estrogen bioluminescent reporter construct was established and
optimized for estrogen receptor mutation study. Through site-directed mutagenesis, five yeast
bioreporters harboring separately the five selected hER mutations were constructed. A list of 12
EDCs including the natural estrogen 17β-estradiol (E2), synthetic hormones, plasticizer,
phytoestrogen and industrial compound were evaluated with the wildtype and mutant hER yeast
bioreporters. Out of the five mutants, Glu353Val mutant showed the most drastic decrease in
the response to all 12 EDCs compared to the wildtype, further confirming the critical role of
Glu353 for ligand-receptor interaction. Met396Val didn’t show any significant difference with the
wildtype in response to the 12 EDCs. Asp351Tyr and Leu525Ala showed moderately decreased
response to tested EDCs compared to the wildtype. Compared to the other mutants, Asp538Gly
produced an interesting response to these EDCs. Out of the 12 tested EDCs, only 4 of them, E2,
EE2, DES and resveratrol, elicited identical or reduced response compared to the wildtype,
whereas the rest of 8 ligands all exhibited elevated potency when been exposed to Asp538Gly
mutant. The EDCs showing significant elevated potency with Asp538Gly mutant include common
phytoestrogens, industrial compounds that are easily accessible either passively or proactively in
daily life. The fact that Asp538Gly mutation causes elevated potency for these ligands in the yeast
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bioreporter raises health alert especially for breast cancer patients due to the high frequency of
this mutation in breast cancer metastatic tumors. When comparing the response patterns of
mutant and wildtype bioreporter to the 12 EDCs, different mutations on hER produced different
response profiles, suggesting that the degree of response changes resulted from a mutation
depends on the actual structure of individual EDCs. In addition, the response trend of hER
mutants for broader spectrum of EDCs may not be readily predictable from the response of the
natural estrogen or other individual EDC. Therefore individual EDC screening for each hER
mutation variant is necessary.
The advantage of yeast estrogen bioreporters is that estrogen receptor is the only nuclear
receptor present in the cell, eliminating possible interference from other nuclear receptors.
However although the yeast cell contains essential coregulators for estrogen receptor to properly
exert transcriptional activation, yeast doesn’t share the same cellular components as human cells.
Therefore further testing in mammalian cells and animal model is warranted to verify the
observed effect of hER mutations. In addition, special care should be taken in such tests when
preparing the medium/nutritious supplements, as weak estrogenic compounds present in the
medium/food could possibly cause unexpected estrogen receptor activation.
When comparing the results form computational modelling and the yeast bioassay, the
agreement between these two approaches seem to depend on the location of the mutation on
hER. For residues inside the binding pocket or have direct contact with the ligand (i.e. Glu353 and
Leu525), molecular docking predicted similar trends as what was demonstrated in the yeast
bioassay. Yet for residues outside the binding pocket such as Asp351 and Asp538, computational
simulation failed to report results with good agreement with yeast bioassay. Part of the reason
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is that changes of transcriptional activity, as tested in the yeast bioassay, is determined not only
by ligand binding affinity, but also interaction with other regulatory proteins. To further decipher
the mode of action for estrogen receptor, further understanding on two main aspects are needed.
Firstly, the structural basis of the whole ER protein, including both the N-terminal domains and
C-terminal domains, and the interaction between the domains should be addressed. Secondly,
the type and structure of coregulators, machinery of interactions between ER and coregulators
in different cell type needs to be elicited as well. As the function estrogen receptor involves a
series of complex interactions, these knowledge could also bring new therapeutic targets for
estrogen receptor related disease.
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